

CITATION REPORT

List of articles citing

Erectile dysfunction

DOI: 10.1056/nejm200006153422407

New England Journal of Medicine, 2000, 342, 1802-13.

Source: <https://exaly.com/paper-pdf/32288456/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1260	Pharmacotherapy for erectile dysfunction. 2000 , 21, 484-9		95
1259	PENILE ANATOMY UNDER THE PUBIC ARCH: RECONSTRUCTIVE IMPLICATIONS. 2001 , 166, 225-230		39
1258	Trends in the Rate of Self-Report and Diagnosis of Erectile Dysfunction in the United States 1990-1998. 2001 , 9, 33-41		7
1257	Insulin-like growth factor-I promotes proliferation and migration of cavernous smooth muscle cells. 2001 , 280, 1307-15		30
1256	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23		65
1255	INCIDENCE OF ERECTILE DYSFUNCTION IN ITALIAN MEN WITH DIABETES. 2001 , 166, 1368-1371		54
1254	Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34		71
1253	VASCULAR ENDOTHELIAL GROWTH FACTOR PROMOTES PROLIFERATION AND MIGRATION OF CAVERNOUS SMOOTH MUSCLE CELLS. 2001 , 166, 354-360		45
1252	The pathophysiological role of prostaglandins in penile erection. 2001 , 2, 799-811		4
1251	Testosterone and cardiovascular diseases. 2001 , 297-332		5
1250	Management of erectile dysfunction secondary to treatment for localized prostate cancer. 2001 , 8, 540-5		16
1249	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. 2001 , 11, 625-30		2
1248	Current World Literature. 2001 , 11, 637-656		
1247	Current World Literature. 2001 , 13, 343-370		
1246	Current World Literature. 2001 , 14, 387-421		
1245	Gene therapy: future therapy for erectile dysfunction. 2001 , 2, 480-7		9
1244	Neurogenic erectile dysfunction. 2001 , 11, 285-94		13

1243	Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. 2001 , 88, 596-601	1
1242	A new potential of blood oxygenation level dependent (BOLD) functional MRI for evaluating cerebral centers of penile erection. 2001 , 13, 73-81	133
1241	Sex, the heart, and sildenafil. 2001 , 26, 388-415	4
1240	What's new in urology. 2001 , 193, 179-201	1
1239	Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. 2001 , 22, 342-88	164
1238	Common Drug Pathways and Interactions. 2002 , 15, 249-255	5
1237	Patient satisfaction with testosterone supplementation for the treatment of erectile dysfunction. 2002 , 48, 433-42	16
1236	A role for the melanocortin 4 receptor in sexual function. 2002 , 99, 11381-6	268
1235	Authors' Reply. 2002 , 36, 1974-1974	
1234	Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. 2002 , 288, 351-7	366
1233	Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. 2002 , 25, 1336-9	207
1232	Overview of the cardiovascular effects of tadalafil. 2002 , 4, H32-H47	63
1231	Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. 2002 , 29, 607-10	43
1230	Chapter 6. Phosphodiesterase 5 inhibitors. 2002 , 37, 53-64	12
1229	The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. 2002 , 7, 213-25	160
1228	Erectile dysfunction in patients with diabetes mellitus â advances in treatment with phosphodiesterase type 5 inhibitors. 2002 , 2, 282-287	8
1227	Quality of life after radical prostatectomy or watchful waiting. <i>New England Journal of Medicine</i> , 2002 , 347, 790-6	59.2 573
1226	Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. 2002 , 67, 1033-41	38

1225	Comment: neurologic, psychological, and aggressive disturbances with sildenafil. 2002 , 36, 1973-4; author reply 1974	2
1224	Current World Literature. 2002 , 12, 517-523	
1223	Pharmacological aspects of erectile dysfunction. 2002 , 89, 101-12	14
1222	Brain activation and sexual arousal in healthy, heterosexual males. 2002 , 125, 1014-23	344
1221	Disfunzione erettile. 2002 , 3, 223-238	1
1220	Sexual dysfunction in patients with hypertension: implications for therapy. 2002 , 4, 424-32	50
1219	Vardenafil. 2002 , 11, 1487-96	27
1218	[Erectile dysfunction]. 2002 , 26, 667-90	5
1217	[Prevalence erectile dysfunction in patients with hypertension]. 2002 , 119, 521-6	17
1216	Nitric Oxide Independent Activation of Guanylate Cyclase by YC-1 Causes Erectile Responses in the Rat. 2002 , 167, 2276-2281	60
1215	Oxygen free radicals and the penis. 2002 , 3, 889-97	92
1214	Editorial comment. 2002 , 59, 586-587	3
1213	Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11	117
1212	Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. 2002 , 60, 1077-82	18
1211	Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. 2002 , 23, 92-7	88
1210	The Role of Apomorphine SL in the Treatment of Erectile Dysfunction. 2002 , 1, 4-11	4
1209	Andropause: clinical implications of the decline in serum testosterone levels with aging in men. 2002 , 57, M76-99	300
1208	[Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction]. 2002 , 119, 121-4	8

1207	The Relationship Of Serum Testosterone To Erectile Function In Normal Aging Men. 2002 , 167, 1745-1748	87
1206	Impotencia e hipertensib arterial. 2002 , 119, 534-536	5
1205	Diagnostic Steps In The Evaluation Of Patients With Erectile Dysfunction. 2002 , 168, 615-620	60
1204	Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients?. 2002 , 29, 11-22, vii	10
1203	An Extract From the Bark of Aspidosperma Quebracho Blanco Binds to Human Penile Adrenoceptors. 2002 , 168, 160-163	11
1202	Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. 2002 , 13, 2770-5	57
1201	Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. 2002 , 67, 20-8	67
1200	Erectile Dysfunction and Symptoms of Sleep Disorders. 2002 , 25, 637-641	34
1199	The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. 2002 , 440, 141-57	55
1198	The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. 2002 , 450, 93-109	73
1197	Viagra (sildenafil citrate) and ophthalmology. 2002 , 21, 485-506	104
1196	Erectile dysfunction and diabetes. 2002 , 2, 60-6	19
1195	Etiology and treatment of erectile failure in diabetes mellitus. 2002 , 2, 501-9	44
1194	The clinical studies of sildenafil for the ageing male. 2002 , 25, 28-33	21
1193	Is there any relation between serum levels of total testosterone and the severity of erectile dysfunction?. 2002 , 14, 167-71	57
1192	The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. 2002 , 14, 245-50	265
1191	Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. 2002 , 14, 259-65	69
1190	Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction. 2002 , 14, 266-70	28

1189	Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation. 2002 , 14, 295-307	37
1188	Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. 2002 , 14 Suppl 2, S33-41	14
1187	Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. 2002 , 14 Suppl 2, S42-7	14
1186	Phosphodiesterase 5 inhibitors: current status and potential applications. 2002 , 1, 674-82	229
1185	Erectile-dysfunction therapies. 2002 , 1, 663-4	14
1184	Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. 2002 , 136, 693-700	46
1183	Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist. 2002 , 136, 701-8	12
1182	Sildenafil for primary and secondary pulmonary hypertension. 2002 , 71, 398-402	70
1181	Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. 2003 , 26, 25-30	62
1180	[Erectile dysfunction -- still a taboo subject]. 2003 , 115, 803-4	
1179	Botulism type B presenting as pure autonomic dysfunction. 2003 , 13, 337-8	37
1178	Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder?. 2003 , 44, 352-4	228
1177	Part I: consultation-liaison literature database: 2003 update and national lists. 2003 , 25, 377-478	3
1176	Introduction: Erectile dysfunction and cardiovascular risk factors. 2003 , 92, 1-2	4
1175	Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. 2003 , 92, 19M-25M	88
1174	Penile neuronal nitric oxide synthase and its regulatory proteins are present in hypothalamic and spinal cord regions involved in the control of penile erection. 2003 , 458, 46-61	15
1173	Erectile dysfunction after surgical treatment. 2003 , 26, 137-40	16
1172	From molecules to mammals: what's NOS got to do with it?. 2003 , 179, 123-35	113

1171	The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. 2003 , 15, 72-8	46
1170	Normal hemodynamic parameters do not always predict the presence of a rigid erection: a quantitative assessment of functional erectile impairment. 2003 , 15, 99-104	4
1169	Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. 2003 , 15, 210-20	148
1168	Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study. 2003 , 15, 221-4	24
1167	Role of some vasoactive mediators in patients with erectile dysfunction: their relationship with angiotensin-converting enzyme and growth hormone. 2003 , 15, 418-25	27
1166	Anatomy and physiology of erection: pathophysiology of erectile dysfunction. 2003 , 15 Suppl 7, S5-8	3
1165	Disfunci3n er3ctil. 2003 , 8, 6092-6100	
1164	Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hypercholesterolemic rabbits. 2003 , 170, 664-8	21
1163	Protocolo diagn3stico de la disfunci3n er3ctil. 2003 , 8, 6125-6127	
1162	Disorders of male sexual function. 2003 , 19, 473-81, v	15
1161	Disfunci3n er3ctil: abordaje y tratamiento integral desde atenci3n primaria. 2003 , 10, 471-483	
1160	Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. 2003 , 169, 1999-200782	
1159	Erectile dysfunction. 2003 , 54, 153-68	66
1158	Pathophysiology of priapism: dysregulatory erection physiology thesis. 2003 , 170, 26-34	98
1157	The value of pituitary magnetic resonance imaging in men with hypogonadism. 2003 , 170, 795-8	38
1156	Potassium superoxide as an alternative reagent for Winterfeldt oxidation of beta-carbolines. 2003 , 5, 43-6	38
1155	New treatments for erectile dysfunction. 2003 , 80 Suppl 4, 40-5; quiz 54-56	3
1154	Vardenafil: a review of its use in erectile dysfunction. 2003 , 63, 2673-703	51

1153	A classification based on peak systolic velocity and end diastolic velocity predicts sildenafil citrate success. 2003 , 37, 502-6	9
1152	Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction. 2003 , 46, 441-4	29
1151	Erectile dysfunction and cardiovascular disease?. 2003 , 18, 493-508	1
1150	New treatments for erectile dysfunction. 2003 , 1, 40-45	5
1149	Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. 2003 , 89, 251-3	307
1148	An update on the PDE-5 inhibitors (PDE-5i). 2003 , 24, S52-8	17
1147	Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. 2003 , 28, 291-7	4
1146	Sleep apnea and cardiovascular disease. Implications for understanding erectile dysfunction. 2003 , 28, 298-303	16
1145	BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. 2003 , 61, 464-7	61
1144	Serum androgen levels in men: impact of health status and age. 2003 , 61, 629-33	51
1143	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. 2003 , 61, 8-14	123
1142	Colour Doppler ultrasound of the penis. 2003 , 58, 514-23	106
1141	Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH ₂ induces penile erection via brain and spinal melanocortin receptors. 2003 , 118, 755-62	62
1140	Androgens and cardiovascular disease. 2003 , 24, 313-40	579
1139	New achievements and pharmacotherapeutic approaches to impotence in the elderly. 2003 , 15, 222-33	2
1138	Sequence and structure-activity relationship of a scorpion venom toxin with nitrenergic activity in rabbit corpus cavernosum. 2003 , 17, 485-7	18
1137	New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. 2003 , 123, 79-80	
1136	Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. 2003 , 100, 5531-6	50

1135	Phosphodiesterase type 5 (PDE5) inhibitors. 2003 , 41, 249-306	23
1134	eHEART: www.heartjnl.com. 2003 , 89, 254-254	
1133	Protein inhibitor of nitric oxide synthase (NOS) and the N-methyl-D-aspartate receptor are expressed in the rat and mouse penile nerves and colocalize with penile neuronal NOS. 2003 , 68, 478-88	38
1132	Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. 2003 , 43, 260-7	73
1131	Incidence of erectile dysfunction and characteristics of patients before and after the introduction of sildenafil in the United Kingdom: cross sectional study with comparison patients. 2003 , 326, 424-5	21
1130	Erectile dysfunction. 2003 , 103, 48-57; quiz 57-8	5
1129	The clinical evaluation of common sexual concerns. 2003 , 8, 217-24	4
1128	Changes in Male Sexuality. 2003 , 719-726	2
1127	Assessment of the efficacy of Viagra (sildenafil citrate) using the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS). 2003 , 71, 100-2	5
1126	Erectile dysfunction and vascular disease. What is the connection?. 2003 , 114, 30-4, 39-40	14
1125	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. 2003 , 9, 77-95	60
1124	Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. 2004 , 241-254	1
1123	Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction. 2004 , 5, 923-32	11
1122	Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. 2004 , 164, 514-20	65
1121	Review: Risk factor assessment of erectile dysfunction. 2004 , 4, 157-161	
1120	A 66-year-old man with sexual dysfunction. 2004 , 291, 2994-3003	19
1119	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250	1
1118	Erectile dysfunction: management update. 2004 , 170, 1429-37	70

1117	Prescribing viagra in an ethically responsible fashion. 2004 , 29, 739-49	7
1116	Male and Female Sexual Dysfunction: Epidemiology, Pathophysiology, Classifications, and Treatment. 2004 , 573-585	0
1115	Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum. 2004 , 309, 587-93	17
1114	Vardenafil treatment for erectile dysfunction. 2004 , 38, 77-85	25
1113	Alternative therapies for male and female sexual dysfunction. 2004 , 32, 161-73	25
1112	ANDROPAUSE: ENDOCRINOLOGY, ERECTILE DYSFUNCTION, AND PROSTATE PATHOPHYSIOLOGY. 2004 , 50, 45-68	4
1111	A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. 2004 , 30, 88-90	39
1110	Sexual dysfunction and diabetes. 2004 , 58, 358-62	35
1109	Vardenafil--PDE5 inhibitor number 3. 2004 , 58, 229	1
1108	The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ. 2004 , 93, 97-9	42
1107	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. 2004 , 94, 1301-9	59
1106	Overactive corpus cavernosum: a novel cause of erectile dysfunction. <i>Andrologia</i> , 2004 , 36, 378-83	2.4 7
1105	The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. 2004 , 66, 367-74	24
1104	Challenges in the assessment of erectile dysfunction and treatment with oral therapies: review with case examples. 2004 , 16, 428-40	
1103	Tadalafil and vardenafil. 2004 , 3, 295-6	9
1102	Cardiology and vascular disorders. 2004 , 3, S13-S17	
1101	Deep brain stimulation of the thalamus can influence penile erection. 2004 , 16, 91-4	30
1100	Feline penile erection induced by topical glans penis application of combination alprostadil and SEPA (Topiglan). 2004 , 16, 73-7	6

1099	Screening for erectile dysfunction as part of periodic examination programs--concept and implementation. 2004 , 16, 341-5	10
1098	Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. 2004 , 16, 135-42	67
1097	Thalamus and penile erection. 2004 , 16, 505-11	12
1096	Document for the general public. Spanish consensus panel on erectile dysfunction. 2004 , 16 Suppl 2, S7-9	
1095	Specific aspects of erectile dysfunction in endocrinology. 2004 , 16 Suppl 2, S10-2	10
1094	Specific aspects of erectile function in urology/andrology. 2004 , 16 Suppl 2, S18-25	
1093	Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). 2004 , 16, 412-7	12
1092	Health care cost implications of sildenafil citrate. 2004 , 1, 141-9	2
1091	Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. 2004 , 1, 161-7	38
1090	Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil. 2004 , 502, 163-7	26
1089	Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. 2004 , 46, 73-9	30
1088	Physiology and biochemistry of erections. 2004 , 23, 93-100	22
1087	Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. 2004 , 27, 114-19	49
1086	Evaluation of penile perfusion by color-coded duplex sonography in the management of erectile dysfunction. 2004 , 22, 361-4	45
1085	Erectile dysfunction is a signal of risk for significant medical comorbidities: A primary care view. 2004 , 1, 129-136	7
1084	Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. 2004 , 1, 137-141	9
1083	Gene therapy treatments for erectile and bladder dysfunction. 2004 , 5, 52-60	13
1082	Synthesis and SAR of tetracyclic pyrroloquinolones as phosphodiesterase 5 inhibitors. 2004 , 12, 1505-15	22

1081	Erectile dysfunction: symptom or disease?. 2004 , 27, 80-95	22
1080	Topical alprostadil cream for the treatment of erectile dysfunction. 2004 , 5, 623-32	17
1079	Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. 2004 , 31, 259-73	23
1078	Erectile dysfunction: etiology, evaluation, and treatment options. 2004 , 88, 387-416, xi	8
1077	Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. 2004 , 31, 249-57	19
1076	Efficacy of Vardenafil in Men with Erectile Dysfunction: A Flexible-Dose Community Practice Study. 2004 ,	
1075	Gonadal and erectile dysfunction in diabetics. 2004 , 88, 933-45, xi	10
1074	Novel therapeutic strategies for the treatment of erectile dysfunction. 2004 , 1, 249-257	1
1073	Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. 2004 , 43, 179-84	299
1072	Erectile dysfunction: the earliest sign of generalized vascular disease?. 2004 , 43, 185-6	48
1071	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88	69
1070	Future options for combination therapy in the management of erectile dysfunction in older men. 2004 , 21, 555-64	26
1069	The discovery and development of Viagra [®] (sildenafil citrate). 2004 , 1-13	4
1068	Expression of human prepro-orexin and signaling characteristics of orexin receptors in the male reproductive system. 2004 , 89, 1957-62	77
1067	Neural control of erection. 2004 , 83, 189-201	183
1066	Use of intraurethral alprostadil in patients not responding to sildenafil citrate. 2004 , 63, 951-4	26
1065	Vardenafil provides reliable efficacy over time in men with erectile dysfunction. 2004 , 64, 1187-95	27
1064	Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. 2004 , 64, 998-1003; discussion 1003-4	54

1063	Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). 2004 , 45, 859-63	74
1062	Therapeutic interventions targeting the nitric oxide system: current and potential uses in obstetrics, bone disease and erectile dysfunction. 2004 , 74, 1701-21	5
1061	Elevation of intracavernous pressure and NO-cGMP activity by a new herbal formula in penile tissues of aged and diabetic rats. 2004 , 94, 85-92	34
1060	Nitric oxide release from human corpus cavernosum induced by a purified scorpion toxin. 2004 , 63, 184-9	31
1059	Anatomy of the human penis: the relationship of the architecture between skeletal and smooth muscles. 2004 , 25, 426-31	48
1058	Erectile dysfunction: evaluation and new treatment options. 2004 , 66, 664-71	29
1057	Erectile dysfunction in primary care. 2004 , 29, 42-6, 48-50, 55; quiz 55-7	9
1056	Men's sexual issues. 2004 , 6, 863-915	
1055	ANDROPAUSE: ENDOCRINOLOGY, ERECTILE DYSFUNCTION, AND PROSTATE PATHOPHYSIOLOGY. 2004 , 50, 45-68	7
1054	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. 2004 , 1, 185-196	
1053	Cyclic nucleotide signaling in vascular and cavernous smooth muscle: aging-related changes. 2004 , 16, 57-106	1
1052	Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension. 2004 , 43, 891-3	2
1051	Physiology and Pharmacology of Erectile Dysfunction. 2005 , 1-24	1
1050	Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. 2005 , 23, 233-46	529
1049	Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. 2005 , 112, 2980-5	260
1048	Bibliography for Sleep, Sex, and Eating Disorders. 2005 , 3, 552-553	
1047	Sexual Dysfunction. 2005 , 3, 520-525	5
1046	Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. 2005 , 95, 843-6	46

1045	Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. 2005 , 95 Suppl 4, 12-8	52
1044	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80	153
1043	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. 2005 , 96, 1323-32	78
1042	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. 2005 , 60, 459-68	19
1041	Glutathione levels in patients with erectile dysfunction, with or without diabetes mellitus. 2005 , 28, 156-62	22
1040	Predictors of erectile function improvement in obstructive sleep apnea patients with long-term CPAP treatment. 2005 , 17, 186-90	47
1039	Erectile dysfunction in chronic renal failure patients undergoing hemodialysis in Egypt. 2005 , 17, 180-5	30
1038	Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips. 2005 , 17, 127-33	22
1037	Difficulties in achieving vs maintaining erection: organic, psychogenic and relational determinants. 2005 , 17, 252-8	18
1036	Erectile dysfunction: to prescribe or not to prescribe?. 2005 , 17, 381-2	2
1035	Erectile dysfunction as an early sign of cardiovascular disease. 2005 , 17 Suppl 1, S19-24	54
1034	Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. 2005 , 17 Suppl 1, S25-36	44
1033	Gene and stem cell therapy for erectile dysfunction. 2005 , 17 Suppl 1, S57-63	23
1032	A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. 2005 , 59, 143-9	14
1031	Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke?. 2005 , 48, 512-8; discussion 517-8	119
1030	The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. 2005 , 96, 19M-23M	201
1029	Phosphodiesterase 5 mechanisms and therapeutic applications. 2005 , 96, 29M-31M	43
1028	Sexual dysfunction and cardiovascular disease: integrative concepts and strategies. 2005 , 96, 57M-61M	54

1027	Normal erectile function. 2005 , 7, 13-8	9
1026	The underlying pathophysiology and causes of erectile dysfunction. 2005 , 7, 19-27	21
1025	Assessment, diagnosis, and investigation of erectile dysfunction. 2005 , 7, 29-35	6
1024	The efficacy and safety of PDE5 inhibitors. 2005 , 7, 47-56	28
1023	The therapeutic dilemma: how to use psychotherapy. 2005 , 28 Suppl 2, 81-5	8
1022	Pattern of endocrinal changes in patients with sexual dysfunction. 2005 , 2, 551-8	41
1021	Association between erectile dysfunction and coronary artery disease: a case report study. 2005 , 2, 575-82	24
1020	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. 2005 , 2, 685-98	22
1019	Cholesterol feeding reduces vascular endothelial growth factor signaling in rabbit corporal tissues. 2005 , 2, 634-40	27
1018	T-type (alpha1G) low voltage-activated calcium channel interactions with nitric oxide-cyclic guanosine monophosphate pathway and regulation of calcium homeostasis in human cavernosal cells. 2005 , 2, 620-30; discussion 630-3	17
1017	Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. 2005 , 2, 658-67	75
1016	Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. 2005 , 2, 40-50; discussion 50-2	112
1015	Invited Comments on Billups, K. et al. Erectile Dysfunction Is a Marker for Cardiovascular Disease: Results of the Minority Health Institute Expert Advisory Panel. 2005 , 2, 50	5
1014	Invited Comments on Billups, K. et al. Erectile Dysfunction Is a Marker for Cardiovascular Disease: Results of the Minority Health Institute Expert Advisory Panel. 2005 , 2, 51	
1013	Author's Response. 2005 , 2, 51-52	0
1012	Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. 2005 , 23, 385-92	37
1011	Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition. 2005 , 40, 894-900	35
1010	Erectile dysfunction: interrelationship with the metabolic syndrome. 2005 , 5, 64-9	32

1009	Erectile dysfunction as a marker for vascular disease. 2005 , 6, 439-44	19
1008	Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. 2005 , 6, 476-81	17
1007	Botanical therapies in sexual dysfunction. 2005 , 19, 457-63	22
1006	Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements. 2005 , 339-378	
1005	Imaging erectile dysfunction. 2005 , 17, 113-121	1
1004	Involvement of β -Adrenergic Receptor Activation in Human Corpus Cavernosum Function. 2005 , 72, 57-62	
1003	Effect of sildenafil citrate on the cardiovascular system. 2005 , 38, 1303-11	8
1002	Editorial [Hot Topic: Sexual Medicine Research -PDE5 Inhibitors and Beyond (Executive Editor: Allen D. Seftel)]. 2005 , 11, 3985-3986	
1001	Endothelial nitric oxide synthase gene therapy for erectile dysfunction. 2005 , 11, 4059-67	24
1000	Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction. 2005 , 11, 4029-40	15
999	The nitric oxide signaling pathway in the penis. 2005 , 11, 3987-94	39
998	Tadalafil. 2005 , 85-107	
997	Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. 2005 , 1, 295-301	3
996	Color Doppler US of the postoperative penis: anatomy and surgical complications. 2005 , 25, 731-48	22
995	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93	34
994	Association of erectile dysfunction with cardiovascular risk factors and increasing existing vascular disease in male chinese type 2 diabetic patients. 2005 , 28, 2051-3	14
993	High proportions of erectile dysfunction in men with the metabolic syndrome. 2005 , 28, 1201-3	201
992	Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. 2005 , 28, 1739-44	86

991	Common therapeutic strategies in the management of sexual dysfunction and cardiovascular disease. 2005 , 5, 185-95	5
990	Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. 2005 , 102, 1661-6	196
989	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72	4
988	Construcci3 de una variable subrogada de detecci3 de disfunci3 er3 ctil a partir de la versi3 espa3la del Cuestionario de Satisfacci3 con la Vida 3SAT 832005, 31, 462-470	3
987	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi	34
986	Erectile dysfunction is a signal of risk for cardiovascular disease: a primary care view. 2005 , 32, 977-93, vii	5
985	Decreases in corporeal vascular endothelial growth factor expression precede vasoreactivity changes in cholesterol fed rabbits. 2005 , 173, 1418-22	10
984	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72	0
983	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,	
982	The supraspinal network in the control of erection. 2005 , 9, 941-54	3
981	Transcutaneous electrocavernosography: a tool for recording the electromyographic activity of the corpora cavernosa. 2005 , 174, 629-31	1
980	Indicazioni diagnostiche e terapeutiche nella disfunzione erettile. 2005 , 6, 168-174	
979	Are dehydroepiandrosterone sulphate and lipids associated with erectile dysfunction?. 2005 , 50, 294-9	4
978	Melanocortinerpic control of penile erection. 2005 , 26, 1972-7	21
977	Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?. 2005 , 65, 224-30	10
976	Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. 2005 , 66, 665-70	18
975	Erectile dysfunction: the need to be evaluated, the right to be treated. 2005 , 150, 620-6	14
974	Vardenafil in patients with erectile dysfunction: achieving treatment optimization. 2005 , 26, 604-9	15

973	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. 2005 , 65, 2245-51	24
972	A Randomised Comparison of the Effects of Nebivolol and Atenolol with and without Chlorthalidone on the Sexual Function of Hypertensive Men. 2005 , 25, 409-16	60
971	Frequently asked questions about tadalafil for treating men with erectile dysfunction. 2005 , 2, 141-157	1
970	Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. 2005 , 32, 403-17, v	81
969	Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. 2005 , 22, 823-44	17
968	Aging in the HypothalamicâPituitaryâTesticular Axis. 2006 , 2697-2728	5
967	Erectile dysfunction as a generalized vascular dysfunction. 2006 , 19, 341-6	25
966	The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome. 2006 , 5, 767-772	5
965	Psychological, Social, and Behavioural Benefits for Men Following Effective Erectile Dysfunction (ED) Treatment: Men Who Enjoy Better Sex Experience Improved Psychological Well-Being. 2006 , 5, 773-778	6
964	Erectile dysfunction. 2006 , 175, S25-31	46
963	Editorial comment. 2006 , 176, 1085-1085	
962	Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. 2006 , 49, 5363-71	29
961	Psycho-biological correlates of free-floating anxiety symptoms in male patients with sexual dysfunctions. 2006 , 27, 86-93	80
960	Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. 2006 , 27, 165-75	39
959	Erectile dysfunction in heart failure patients. 2006 , 48, 1111-9	62
958	Errori concettuali, diagnostici e terapeutici nella gestione del paziente con disfunzione erettile. 2006 , 7, 203-208	
957	The role of nitric oxide in erectile dysfunction: implications for medical therapy. 2006 , 8, 53-62	112
956	Long-term effect of experimental hypercholesterolemia on cavernosal tissues. 2006 , 67, 431-4	2

955	Sexual function after surgery for prostate or bladder cancer. 2006 , 13, 179-87	17
954	Sildenafil in dialysis patients. 2006 , 29, 264-8	12
953	Erectile Dysfunction in Diabetes: An Endothelial Disorder. 2006 , 165-178	1
952	Male Sexual Function. 2006 , 1173-1194	1
951	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9	8
950	Management of the cardinal features of andropause. 2006 , 13, 145-60	19
949	Management of sildenafil treatment failures. 2006 , 16, 449-59	33
948	Cardiovascular disease, metabolic syndrome and erectile dysfunction. 2006 , 16, 435-43	51
947	Etiology and Risk Factors of Erectile Dysfunction. 49-58	5
946	Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. 2006 , 166, 201-6	49
945	The hypoactive corpora cavernosa with degenerative erectile dysfunction: a new syndrome. 2006 , 6, 13	3
944	Effect of sildenafil on arterial stiffness, as assessed by pulse wave velocity, in patients with erectile dysfunction. 2006 , 13, 956-9	4
943	The evolving role of testosterone in the treatment of erectile dysfunction. 2006 , 60, 1087-92	56
942	Hypothesis of human penile anatomy, erection hemodynamics and their clinical applications. 2006 , 8, 225-34	25
941	Role of the brain in the control of erection. 2006 , 8, 259-64	8
940	Tadalafil pharmacokinetics in healthy subjects. 2006 , 61, 280-8	188
939	Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. 2006 , 18, 111-4	34
938	Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. 2006 , 18, 251-7	16

937	Gene transfer for the therapy of erectile dysfunction: progress in the 21st century. 2006 , 18, 19-25	17
936	Vascular risk factors and erectile dysfunction in a cohort of healthy men. 2006 , 18, 489-93	30
935	Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels in the peripheral venous and cavernous blood of diabetics with erectile dysfunction. 2006 , 18, 544-9	12
934	Manipulative treatment for idiopathic impotence in a 24-year-old water polo player. 2006 , 9, 66-71	1
933	Synthesis of Tadalafil Analogues. 2006 , 36, 2627-2632	5
932	Treatment options for autonomic neuropathies. 2006 , 8, 119-32	10
931	Sexualstörungen bei Diabetes mellitus. 2006 , 2, 149-157	2
930	Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. 2006 , 7, 490-6	22
929	Priapism: new concepts in the pathophysiology and new treatment strategies. 2006 , 7, 497-502	47
928	La dysfonction érectile, un marqueur précoce d'atteinte cardio-vasculaire. 2006 , 16, 24-27	1
927	Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. 2006 , 3, 223-32	25
926	Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design. 2006 , 3, 492-503	23
925	ANDROTEST: a structured interview for the screening of hypogonadism in patients with sexual dysfunction. 2006 , 3, 706-715	102
924	The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. 2006 , 3, 960-975	26
923	Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum. 2006 , 544, 138-45	21
922	EAU Guidelines on erectile dysfunction: an update. 2006 , 49, 806-15	204
921	Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. 2006 , 48, 128-33	45
920	Synthesis of 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-n-propoxyphenyl]-7-n-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]-[2,1-b]imidazole HCl (14C-SK353072 HCl). 2006 , 49, 1141-1149	204

919	Interstitial cells of Cajal in erectile dysfunction. 2006 , 52, 255-62	2
918	Shared medical appointments in a pharmacy-based erectile dysfunction clinic. 2006 , 63, 1165-6	5
917	Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. 2006 , 290, R1302-8	25
916	Obesity and Diabetes. 2006 ,	4
915	Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. 2006 , 27, 2632-9	297
914	The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. 2006 , 166, 213-9	181
913	Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. 2007 , 23, 3189-98	10
912	Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. 2007 , 23, 2453-60	26
911	Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. 2007 , 19, 544-50	33
910	Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. 2007 , 293, H2588-96	47
909	Autonomic Nervous System. 2007 , 383-404	4
908	Keine bloÙ BefindlichkeitsstÖung - Die Erektile Dysfunktion bei Diabetes mellitus. 2007 , 5, 105-111	
907	Chloroquine-induced nitric oxide as a potential treatment of erectile dysfunction associated with the metabolic syndrome: the science and the fiction. 2007 , 12, 191-3	1
906	Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. 2007 , 292, H1278-90	119
905	Sildenafil (Viagra) and club drug use in gay and bisexual men: the role of drug combinations and context. <i>American Journal of Mens Health</i> , 2007 , 1, 139-47	2.2 20
904	Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. 2007 , 334, 466-80	14
903	Gene and stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial dysfunction. 2007 , 7, 131-53	9
902	Mouse model of erectile dysfunction due to diet-induced diabetes mellitus. 2007 , 70, 196-201	23

901	Hypogonadism in male outpatients with sarcoidosis. 2007 , 101, 2502-10	18
900	Effect of lithium on endothelium-dependent and neurogenic relaxation of rat corpus cavernosum: role of nitric oxide pathway. 2007 , 16, 54-63	21
899	Metabolic syndrome and endothelial dysfunction and associated high proportions of erectile dysfunction in men: innocent bystanders or accessories to the crime?. 2007 , 75, 370-1	4
898	Time-dependent alteration in cromakalim-induced relaxation of corpus cavernosum from streptozocin-induced diabetic rats. 2007 , 81, 960-9	6
897	Sexual satisfaction among patients after coronary bypass surgery or percutaneous transluminal angioplasty: eight-year follow-up. 2007 , 36, 262-9	22
896	Erectile dysfunction. 2007 , 28, 274-86	10
895	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. 2007 , 34, 507-15, vi	23
894	Disfunci3n er^ ctil tras prostatectom3 radical. 2007 , 5, 277-283	
893	Is the metabolic syndrome an independent risk factor for erectile dysfunction?. 2007 , 177, 651-4	92
892	Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. 2007 , CD002187	50
891	Gene therapy for erectile dysfunction. 2007 , 8, 979-84	2
890	Diabetic Neuropathy. 2007 ,	7
889	[Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. 2007 , 31, 52-7	1
888	Erectile dysfunction. 2007 , 177, 1675-81	73
887	Male Erectile Dysfunction. 2007 , 2, 57-71	2
886	Treatment options for erectile dysfunction. 2007 , 36, 465-79	32
885	The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. 2007 , 178, 591-6; discussion 596	50
884	Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?. 2007 , 262, 89-97	26

883	Changes in the smooth muscle of the corpora cavernosum related to reversal of partial bladder outlet obstruction in rabbits. 2008 , 29, 164-71	7
882	Neurologic Aspects of Sexual Function. 2007 , 355-370	
881	Effects of the aqueous and hexane extracts of <i>Mondia whitei</i> on the sexual behaviour and some fertility parameters of sexually inexperienced male rats. 2006 , 4, 37-46	22
880	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. 2007 , 3, 527-542	1
879	The Role of Endothelium in Erectile Function and Dysfunction. 1541-1549	1
878	Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide. 2007 , 99, 612-8	38
877	The associations among eNOS G894T gene polymorphism, erectile dysfunction and related risk factors. 2007 , 100, 1116-20	18
876	Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors. 2007 , 100, 1385-90	14
875	Correlates of erectile dysfunction in moderate-to-severe chronic obstructive pulmonary disease patients. 2007 , 12, 248-53	51
874	Diagnosis and management of erectile dysfunction in the primary care setting. 2007 , 61, 1198-208	13
873	Neurophysiological basis of penile erection. 2007 , 28, 751-5	33
872	Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders. 2007 , 9, 129-33	13
871	Blood pressure control and sildenafil--carrot stick or sword of Damocles?. 2007 , 100, 552-3	2
870	Is sex only for the healthy and wealthy?. 2007 , 4, 176-182	18
869	Association of risk factors and medical comorbidities with male sexual dysfunctions. 2007 , 4, 1691-700	55
868	The efficacy and safety of vardenafil in East Asian men with erectile dysfunction. 2007 , 4, 753-761	13
867	The first principle of clinical sexuality. 2007 , 4, 853-4	17
866	A mouse model of hypercholesterolemia-induced erectile dysfunction. 2007 , 4, 898-907	46

865	Clinical application of CNS-acting agents in FSD. 2007 , 4 Suppl 4, 280-90	14
864	Optimizing response to phosphodiesterase type 5 inhibitors. 2007 , 4, 1-6	1
863	Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure. 2007 , 4, 110-6	
862	Sexuelle Dysfunktion bei Männern nach Beckenfraktur. 2008 , 10, 141-146	0
861	Anxiolytic and antidepressant characteristics of impaza. 2008 , 145, 735-7	1
860	The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. 2008 , 20, 85-91	78
859	Yohimbine enhances the effect of sildenafil on erectile process in rats. 2008 , 20, 409-17	11
858	Insights of priapism mechanism and rationale treatment for recurrent priapism. 2008 , 10, 88-101	45
857	Sexual and reproductive function in end-stage renal disease and effect of kidney transplantation. 2008 , 10, 441-6	22
856	Homocysteine and copper interact to promote type 5 phosphodiesterase expression in rabbit cavernosal smooth muscle cells. 2008 , 10, 905-13	15
855	Molecular Yin and Yang of erectile function and dysfunction. 2008 , 10, 433-40	9
854	Efficacy of tadalafil in Egyptian and Turkish men with erectile dysfunction. 2006 , 60, 812-9	8
853	Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. 2008 , 65, 848-54	60
852	Hyperprolactinaemia due to hypothalamic-pituitary disease or drug-induced in patients with erectile dysfunction. <i>Andrologia</i> , 2008 , 40, 240-4	2.4 2
851	Human neural crest stem cells transplanted in rat penile corpus cavernosum to repair erectile dysfunction. 2008 , 102, 220-4; discussion 224	40
850	Lower urinary tract symptoms and sexual dysfunction: a common approach. 2008 , 101 Suppl 3, 22-6	26
849	The pharmacological management of intermittent priapismic states. 2008 , 102, 1515-21	17
848	Medical treatments for benign prostatic hyperplasia and sexual function. 2008 , 102 Suppl 2, 8-12	6

847	Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. 2008 , 25, 138-46	97
846	Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial. 2008 , 9, 143	34
845	Comparison of findings on stress myocardial perfusion imaging in men with versus without erectile dysfunction and without prior heart disease. 2008 , 101, 502-5	10
844	The nonadrenergic noncholinergic-mediated relaxation of corpus cavernosum was impaired in chronic lithium-treated rats: improvement with l-arginine. 2008 , 586, 300-5	14
843	Erectile dysfunction in liver transplant patients. 2008 , 8, 2580-9	17
842	Association between psychiatric symptoms and erectile dysfunction. 2008 , 5, 458-68	66
841	Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. 2008 , 5, 1965-76	14
840	Management of ischemic penile gangrene: prompt partial penectomy and other treatment options. 2008 , 5, 2725-33	9
839	The associations among GNB3 C825T polymorphism, erectile dysfunction, and related risk factors. 2008 , 5, 2061-8	10
838	Testosterone and erectile dysfunction. 2008 , 29, 593-604	48
837	Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. 2008 , 68, 209-29	13
836	[Decrease ApoB/ApoA-1 ratio and cardiovascular risk improvement: a tadalafil pleiotropic effect? Preliminary study on healthy volunteers]. 2008 , 18, 1087-91	2
835	Severity of erectile dysfunction at presentation: effect of premature ejaculation and low desire. 2008 , 71, 94-8	26
834	Sexuality: a quality-of-life issue for cancer survivors. 2008 , 24, 71-9	91
833	Association among metabolic syndrome, testosterone level and severity of erectile dysfunction. 2008 , 24, 240-7	15
832	Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. 2008 , 196, 313-319	24
831	Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. 2008 , 42, 437-40	30
830	Physiological regulation of penile arteries and veins. 2008 , 20, 17-29	123

829	Color Doppler US of the Penis. 2008 ,	4
828	Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. 2008 , 594868	19
827	Erectile dysfunction and testosterone deficiency. 2009 , 37, 108-122	44
826	Epidemiology and pathophysiology of male sexual dysfunction. 2008 , 20 Suppl 1, S3-10	24
825	Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease. 2008 , 20, 150-6	5
824	Relaxant effects of an alkaloid-rich fraction from <i>Aspidosperma ulei</i> root bark on isolated rabbit corpus cavernosum. 2008 , 20, 255-63	7
823	Erectile dysfunction as a harbinger for increased cardiometabolic risk. 2008 , 20, 236-42	52
822	Stem and endothelial progenitor cells in erection biology. 2008 , 20, 243-54	14
821	New horizons in erectile and endothelial dysfunction research and therapies. 2008 , 20 Suppl 2, S2-8	19
820	Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study. 2008 , 20, 418-24	12
819	Pharmacotherapy for erectile dysfunction. 2008 , 17, 679-90	16
818	[Pharmacological, pharmacokinetic, and clinical profile of tadalafil (Cialis)]. 2008 , 131, 469-77	1
817	A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction. 2008 , 31, 522-31	28
816	Tadalafil in the treatment of erectile dysfunction. 2008 , 4, 1315-30	57
815	Endocrinology. 2008 , 127-162	1
814	Can the PDE5 Inhibitor Replace Intracavernosal Injection as a Method for Inducing a Penile Erection during the Evaluation of Erectile Dysfunction Using Penile Duplex Ultrasonography?. 2008 , 49, 641	
813	Gene therapy in the management of erectile dysfunction (ED): past, present, and future. 2009 , 9, 846-54	11
812	Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. 2009 , 3, 99-104	23

811	Obesity and Erectile Dysfunction. 2009 , 5, 183-185	1
810	Has prolactin a role in the hypogonadal status of HIV-infected patients?. 2009 , 8, 43-6	6
809	“Just Take Viagra” Erectile Insurance, Prophylactic Certainty and Deficit Correction in Gay Men: Accounts of Sexuopharmaceutical Use. 2009 , 12, 746-764	14
808	Sexual dysfunction in multiple sclerosis. 2009 , 9, 341-50	79
807	Sexual dysfunction in the older man. 2009 , 19, 237-248	10
806	PDE5 inhibitors: in vitro and in vivo pharmacological profile. 2009 , 15, 3464-75	53
805	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 2009 , 21, 149-57	12
804	Daily patterns of sexual intercourse attempts by men with erectile dysfunction treated with tadalafil: influence of age and marital status. 2009 , 21, 285-91	4
803	How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. 2009 , 21, 327-35	16
802	Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management. 2009 , 10, 116	28
801	Treatment of penile deep dorsal venous leakage of erectile dysfunction by embedding the deep dorsal vein of the penis: a single center experience with 17 patients. 2009 , 6, 1467-73	5
800	Erectile dysfunction in end-stage liver disease men. 2009 , 6, 1395-401	26
799	Erectile function in two-kidney, one-clip hypertensive rats is maintained by a potential increase in nitric oxide production. 2009 , 6 Suppl 3, 279-85	6
798	Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. 2009 , 6, 1414-22	57
797	Vascular risk factors as predictors of sexual function following coronary artery bypass graft. 2009 , 6, 2017-23	9
796	Peripheral vascular disease and erectile dysfunction as predictors of mortality in heart failure patients. 2009 , 6, 1999-2007	7
795	Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. 2009 , 6, 2187-96	32
794	The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. 2009 , 6, 3158-65	27

793	Sleep apnea is an independent correlate of erectile and sexual dysfunction. 2009 , 6, 3147-57	84
792	Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction. 2009 , 6, 2851-7	7
791	Erectile dysfunction after external beam radiotherapy for prostate cancer. 2009 , 55, 227-34	71
790	Editorial comment on: Erectile dysfunction after external beam radiotherapy for prostate cancer. 2009 , 55, 234-5	
789	Sexual dysfunction after liver transplantation. 2009 , 15 Suppl 2, S50-6	26
788	Erectile dysfunction in myotonic dystrophy type 1 (DM1). 2009 , 256, 657-9	3
787	Obstructive sleep apnea and erectile dysfunction: still a neglected risk factor?. 2009 , 13, 3-10	37
786	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. 2009 , 48, 1318, 1320-9	7
785	Assessment of erectile dysfunction in diabetic patients. 2009 , 32, 176-85	20
784	Construction of cavernosum smooth muscle using umbilical artery smooth muscle cells seeded on acellular corporal collagen matrices. 2009 , 32, 514-23	20
783	A critical appraisal of erectile function in animal models of diabetes mellitus. 2009 , 32, 93-114	23
782	Risk factors for erectile dysfunction in healthy Japanese men. 2010 , 33, 569-73	17
781	Health-related quality of life 3 years after high-dose intensity-modulated radiotherapy with gold fiducial marker-based position verification. 2009 , 103, 762-7	25
780	Acupuncture for treating erectile dysfunction: a systematic review. 2009 , 104, 366-70	29
779	Mad honey sex: therapeutic misadventures from an ancient biological weapon. 2009 , 54, 824-9	22
778	Penile reconstruction. 2009 , 470-481	
777	Chronic ethanol consumption induces cavernosal smooth muscle dysfunction in rats. 2009 , 74, 1250-6	23
776	Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. 2009 , 158, 484-502	118

775	Cyclic GMP-hydrolyzing phosphodiesterases. 2009 , 367-408		28
774	Combined cardiac sympathetic excitation and vagal impairment in patients with non-organic erectile dysfunction. 2009 , 120, 348-52		31
773	Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. 2009 , 69, 1111-6		32
772	Brain effects of melanocortins. 2009 , 59, 13-47		76
771	Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor?. 2009 , 30, 515-9		2
770	Cardiovascular Endocrinology. 2009 ,		2
769	cGMP: Generators, Effectors and Therapeutic Implications. 2009 ,		13
768	Diabetes, obesity, and erectile dysfunction. 2009 , 6 Suppl 1, 4-16		49
767	The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. 2009 , 10, 155-60		22
766	Small-vessel lower extremity arterial disease and erectile dysfunction: The Rancho Bernardo study. 2009 , 203, 620-5		11
765	Análisis comparativo termográfico y de gases sanguíneos de los cuerpos cavernosos del varón en el curso de diferentes tipos de erección. 2009 , 7, 5-13		
764	Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 139-148	6.4	76
763	Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. 2009 , 19, 7-12		16
762	Efficacy and safety of vardenafil in men with diabetes and erectile dysfunction. 2009 ,		
761	Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function?. 2009 , 15, 3506-20		9
760	Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?. 2010 , 89, 1425-9		36
759	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. 2010 , 135-172		
758	Phosphodiesterase Inhibitors in Vascular Ischemia: A Case Report and Review of Their Use in Ischemic Conditions. <i>Canadian Journal of Plastic Surgery</i> , 2010 , 18, 5-9		5

- 757 Treatment of erectile dysfunction in the older diabetic patient. **2010**, 6, 9-29
- 756 Cambios morfofuncionales penianos tras prostatectomía radical: revisión de la evidencia. **2010**, 34, 579-585
- 755 A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma. **2010**, 878, 2891-5 31
- 754 Évaluation des effets prosexuels des extraits de *Bridelia ferruginea* chez le rat mâle naïf. **2010**, 20, 209-215 1
- 753 Sexualstörungen bei Diabetes mellitus. **2010**, 6, 389-404
- 752 Erectile dysfunction as a complication of heart failure. **2010**, 7, 194-201 9
- 751 Recent advances in the medical and surgical treatment of priapism. **2010**, 11, 405-13 6
- 750 Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. **2010**, 25, 115-21 17
- 749 d-Serine modulates neurogenic relaxation in rat corpus cavernosum. **2010**, 79, 1791-6 11
- 748 Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. **2010**, 7, 3011-22 34
- 747 Role of adenosine signaling in penile erection and erectile disorders. **2010**, 7, 3553-64 38
- 746 Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?. **2010**, 7, 858-72 55
- 745 Sexual disorders in infertile couples. **2010**, 7, 1868-76 91
- 744 Correlation between the European System for Cardiac Operative Risk Evaluation and sexual function after coronary artery bypass graft surgery. **2010**, 7, 2158-2165 1
- 743 Failure of PDE5 inhibitor use: a case of nonresponder? (CME). **2010**, 7, 1321-3 2
- 742 Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. **2010**, 7, 1726-33 56
- 741 Angiogenesis therapy for the treatment of erectile dysfunction. **2010**, 7, 2554-63 12
- 740 Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. **2010**, 7, 2842-50 25

739	Vasculogenic erectile dysfunction and metabolic syndrome. 2010 , 7, 3997-4002		16
738	Prevalence of erectile dysfunction in systolic heart failure patients in a developing country: Tbilisi, Georgia, Eastern Europe. 2010 , 7, 3991-6		3
737	Sexual behavior in the United States: results from a national probability sample of men and women ages 14-94. 2010 , 7 Suppl 5, 255-65		398
736	Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. 2010 , 5, 1927-36		17
735	Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. 2010 , 76, 882-7		47
734	Intima-media thickness of carotid arteries and erectile dysfunction in hemodialysis patients. 2010 , 14, 510-4		16
733	8-isoprostane F ₂ is up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide. 2010 , 106, 1794-8		7
732	Endothelial dysfunction and erectile dysfunction in the aging man. 2010 , 17, 38-47		91
731	Sexual dysfunction in uraemic patients undergoing haemodialysis: predisposing and related conditions. <i>Andrologia</i> , 2010 , 42, 166-75	2.4	8
730	Corpus cavernosum electromyography: could it be a parameter to predict ageing?. <i>Andrologia</i> , 2010 , 42, 343-8	2.4	1
729	Male Sexual Dysfunction. 2010 , 408-413		1
728	Correlation between penile cavernosal artery blood flow and retinal vascular findings in arteriogenic erectile dysfunction. 2010 , 4, 1047-51		3
727	Some arachnidan peptides with potential medical application. 2010 , 16, 8-33		6
726	Sexual Disorders and Sexual Dysfunction. 2010 , 323-335		1
725	Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study. 2010 , 51, 647-52		13
724	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. 2010 , 4, 159-71		23
723	A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction. 2010 , 2010,		17
722	A side effect resource to capture phenotypic effects of drugs. 2010 , 6, 343		608

721	The impact of irritative lower urinary tract symptoms on erectile dysfunction in aging Taiwanese males. <i>Aging Male</i> , 2010 , 13, 179-83	2.1	11
720	Sexual Function and Dysfunction in Men and Women. 2010 , 707-715		
719	Is there a relationship between Behçet disease and erectile dysfunction?. 2010 , 36, 380-386		2
718	Is erectile dysfunction a predictor of cardiovascular events or stroke? A prospective study using a validated questionnaire. 2010 , 22, 25-9		43
717	Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed men. 2010 , 22, 30-5		4
716	Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits. 2010 , 22, 120-6		5
715	Clinical Andrology. 2010 ,		1
714	Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. 2010 , 122, 165-75		50
713	Erectile dysfunction may improve by blood pressure control in patients with high-risk hypertension. 2010 , 122, 51-6		26
712	The future is today: emerging drugs for the treatment of erectile dysfunction. 2010 , 15, 467-80		61
711	Effect of Alcohol Consumption on the Risk of Erectile Dysfunction. 2010 , 21, 163-168		2
710	Male and Female Sexual Function and Dysfunction; Andrology. 2010 , 184, 2473-2476		
709	Functional expression of a recombinant toxin - rPnTx2-6 - active in erectile function in rat. 2010 , 56, 1172-80		12
708	Reduced vasoreactivity in corpus cavernosum of the akita mouse. 2010 , 31, 547-51		3
707	Great Burdock Extract on Rabbit Corpus Cavernosum. 2010 , 2, 98-104		
706	Penile morphometric changes after radical prostatectomy: Evidence-based. 2010 , 34, 579-585		1
705	Gene therapy as future treatment of erectile dysfunction. 2010 , 10, 1305-14		24
704	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. 2010 , 19, 1427-37		61

703	The mechanism of vacuum constriction devices in penile erection: the NO/cGMP signaling pathway?. 2010 , 75, 422-4	9
702	Assailants' sexual dysfunction during rape: prevalence and relationship to genital trauma in female victims. 2010 , 38, 529-35	16
701	Clinical features and treatment options for Chinese patients with severe primary erectile dysfunction. 2010 , 76, 387-90	8
700	Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 2010 , 11, 1109-22	63
699	Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. 2010 , 28, 15-22	69
698	Molecular targets for diabetes mellitus-associated erectile dysfunction. 2010 , 9, 565-78	29
697	The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues. 2010 , 20, 211-7	7
696	Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. 2010 , 56, 62-7	52
695	Intracavernosal administration of sodium nitrite as an erectile pharmacotherapy. 2010 , 88, 770-6	10
694	Tadalafil. 2011 , 36, 287-329	13
693	Ophthalmoscopy for general practitioners. 2011 , 53, 501-501	
692	Regular nonsteroidal anti-inflammatory drug use and erectile dysfunction. 2011 , 185, 1388-93	30
691	Medical implications of erectile dysfunction. 2011 , 95, 213-21	13
690	Lower urinary tract symptoms and erectile dysfunction. 2011 , 22, 135-140	1
689	Association of nocturnal penile rigidity with testosterone, metabolic syndrome, and other variables: A prospective cross-sectional pilot study. 2011 , 35, 459-467	
688	Newer phosphodiesterase inhibitors: comparison with established agents. 2011 , 38, 155-63	10
687	A2B adenosine receptor contributes to penile erection via PI3K/AKT signaling cascade-mediated eNOS activation. 2011 , 25, 2823-30	32
686	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. 2011 , 63, 811-59	213

685	Practical Urology: Essential Principles and Practice. 2011 ,	9
684	Evaluation and treatment of erectile dysfunction. 2011 , 95, 201-12	17
683	Contemporary Treatment of Erectile Dysfunction. 2011 ,	2
682	Combined intracavernous vasoactive drugs and sildenafil citrate in treatment of severe erectile dysfunction not responding to on-demand monotherapy. 2011 , 9, 153-8	
681	Priapism in the United States: the changing role of sickle cell disease. 2011 , 201, 468-74	14
680	Hormonal profile, the PROGINS polymorphism, and erectile dysfunction complaints: data from a population-based survey. 2011 , 95, 621-4	12
679	Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. 2011 , 77, 761.e1-7	20
678	Effects of androgen on the expression of vascular endothelial growth factor in the penile corpus cavernosum. 2011 , 77, 1381-6	8
677	Nueva formulaci3n bucodispersable de vardenafilo para el tratamiento de la disfunci3n er3ctil. 2011 , 9, 21-29	
676	Dynamic observation of penile hemodynamic change in patients with vasculogenic erectile dysfunction after prostaglandin E1 treatment. 2011 , 6, 3770-3775	
675	Sexual Dysfunctions. 2011 ,	
674	Hydrogen therapy may be a promising, safe and effective treatment for diabetic erectile dysfunction: a hypothesis. 2011 , 1, 11	
673	Erectile dysfunction: a disease marker for cardiovascular disease. 2011 , 19, 5-11	66
672	The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study. 2011 , 107, 264-7	5
671	Can simvastatin improve erectile function and health-related quality of life in men aged >40 years with erectile dysfunction? Rationale and design of the Erectile Dysfunction and Statins (EDS) Trial [ISRCTN66772971](1). 2011 , 108, 1850-4	6
670	Long-term efficacy and safety of self-intracavernous injection of prostaglandin E1 for treatment of erectile dysfunction in China. <i>Andrologia</i> , 2011 , 43, 208-12	2.4 7
669	Sexual evaluation and treatment of ageing males with haemophilia. 2011 , 17, 875-83	9
668	Age-related changes in kallikreins-kinins system in rat corpus cavernosum. 2011 , 34, 33-40	8

667	Lithium decreased endothelium-mediated, but not nonadrenergic noncholinergic, relaxation of guinea pig corpus cavernosum in vitro: a role for nitrenergic system. 2011 , 25, 191-9	5
666	Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. 2011 , 23, 320-30	6
665	Poly(ADP-Ribose) polymerase inhibition improves erectile function in diabetic rats. 2011 , 8, 1002-14	15
664	Increased risk of stroke among men with erectile dysfunction: a nationwide population-based study. 2011 , 8, 240-6	38
663	In vitro and in vivo animal models in priapism research. 2011 , 8, 347-59	6
662	The high risk of obstructive sleep apnea--an independent risk factor of erectile dysfunction in ST-segment elevation myocardial infarction patients. 2011 , 8, 1434-8	11
661	Increased risk for cancer following erectile dysfunction: a nationwide population-based follow-up study. 2011 , 8, 1513-20	18
660	New classification of anomalous venous drainage using caverno-computed tomography in men with erectile dysfunction. 2011 , 8, 1439-44	15
659	Impaired erectile function in CD73-deficient mice with reduced endogenous penile adenosine production. 2011 , 8, 2172-80	10
658	The Subjective Sexual Arousal Scale for Men (SSASM): preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal. 2011 , 8, 2255-68	3
657	Evaluation of sexual function in hypertensive men receiving treatment: a review of current guidelines recommendation. 2011 , 8, 2405-14	19
656	Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. 2011 , 8, 2215-26	23
655	Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. 2011 , 8, 3418-32	71
654	Population-based estimates of medical comorbidities in erectile dysfunction in a Taiwanese population. 2011 , 8, 3316-24	28
653	<i>Mondia whitei</i> (Apocynaceae): A review of its biological activities, conservation strategies and economic potential. 2011 , 77, 960-971	20
652	Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. 2011 , 60, 1020-6	23
651	[Association of nocturnal penile rigidity with testosterone, metabolic syndrome, and other variables: a prospective cross-sectional pilot study]. 2011 , 35, 459-67	4
650	[Penile Doppler ultrasound: contribution to the management of erectile dysfunction]. 2011 , 36, 33-40	1

649	The quality of lifestyle and the quality of life. 2011 , 171, 1819-20	2
648	Traditional Chinese Medicine. 2011 ,	1
647	Natural therapies used by adult men for the treatment of erectile dysfunction, benign prostatic hyperplasia, and for augmenting exercise performance. 2011 , 24, 323-31	5
646	Testosterone replacement therapy in males with erectile dysfunction. 2011 , 24, 298-306	9
645	Sexual Dysfunctions of HIV-Positive Men: Associated Factors, Pathophysiology Issues, and Clinical Management. 2011 , 2011, 854792	16
644	Effect of an Ethanol Extract of <i>Scutellaria baicalensis</i> on Relaxation in Corpus Cavernosum Smooth Muscle. 2012 , 2012, 148929	2
643	Sexual and reproductive abnormalities in patients with spinal cord injuries. 2012 , 38, 159-167	
642	Assessment of the effect of unilateral and bilateral prostaglandin E1 intracavernosal injection on cavernosal peak systolic velocity. 2012 , 2, 12-15	
641	Adipose tissue-derived stem cell-seeded small intestinal submucosa for tunica albuginea grafting and reconstruction. 2012 , 109, 2090-5	51
640	Effect of long-term administration of cordycepin from <i>Cordyceps militaris</i> on testicular function in middle-aged rats. 2012 , 78, 1620-5	14
639	Retinal vessel tortuosity in response to hypobaric hypoxia. 2012 , 13, 263-8	10
638	Stem cell therapy for erectile dysfunction: a critical review. 2012 , 21, 343-51	81
637	Is penile atherosclerosis the link between erectile dysfunction and cardiovascular risk? An autopsy study. 2012 , 24, 137-40	18
636	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. 2012 , 125, 1058-72	202
635	Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group. 2012 , 30, 3408-16	141
634	Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. 2012 , 2012, 627278	44
633	Sickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia. 2012 , 2012, 723520	9
632	Dysfonction ^ rectile : prise en charge diagnostique et th^ rapeutique. 2012 , 9, 1-11	

631 Male Sexual Arousal Disorder. **2012**, 32-67

630 Excessive penile norepinephrine level underlies impaired erectile function in adenosine A1 receptor deficient mice. **2012**, 9, 2552-61

10

629 [Guidelines-oriented diagnostics of dyslipidemia]. **2012**, 37, 773-82

628 [Male sexuality in the elderly]. **2012**, 51, 1399-413

1

627 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). **2012**, 223, 1-68

286

626 Metabolic syndrome: a potential and independent risk factor for erectile dysfunction in the Chinese male population. **2012**, 80, 1287-92

10

625 The relaxation effect and mechanism of action of higenamine in the rat corpus cavernosum. **2012**, 24, 77-83

6

624 Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. **2012**, 39, 77-88

19

623 Emerging tools for erectile dysfunction: a role for regenerative medicine. **2012**, 9, 520-36

27

622 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). **2012**, 33, 1635-701

2797

621 Sexual Desire is Also a Many Splendored Thing. **2012**, 49, 409-411

620 European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). **2012**, 18, 505-617

233

619 Dancing with Science, Ideology, and Technique. **2012**, 49, 408-409

1

618 A Chinese herbal formula, Shuganyiyang capsule, improves erectile function in male rats by modulating Nos-CGMP mediators. **2012**, 79, 241.e1-6

13

617 Multicenter pathophysiologic investigation of erectile dysfunction in clinic outpatients in China. **2012**, 79, 601-6

8

616 Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. **2012**, 80, 134-9

19

615 Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. **2012**, 164, 21-8

58

614 Biochemical and genetic markers of erectile dysfunction. **2012**, 57, 139-62

4

613	Effects of chronic stress on penile corpus cavernosum of rats. 2012 , 33, 735-9	28
612	Role of hydrogen sulfide in the physiology of penile erection. 2012 , 33, 529-35	19
611	NADPH oxidase activation: a mechanism of erectile dysfunction in a rat model of sleep apnea. 2012 , 33, 1186-98	18
610	Sexual dysfunction following radical prostatectomy. 2012 , 33, 1143-54	23
609	Management of erectile dysfunction: great progress, greater promise. 2012 , 33, 1107-10	3
608	Avanafil for treatment of erectile dysfunction: review of its potential. 2012 , 8, 517-23	29
607	European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2012 , 19, 403-88	196
606	Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). 2012 , 65, 937.e1-937.e66	7
605	[Influence of aging on male sexual health]. 2012 , 22 Suppl 1, S7-13	3
604	Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. 2012 , 58, 3-14	53
603	Animal models of erectile dysfunction (ED): potential utility of non-human primates as a model of atherosclerosis-induced vascular ED. 2012 , 24, 91-100	11
602	Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats. 2012 , 15, 528-37	12
601	Mechanisms in Erectile Function and Dysfunction: An Overview. 2012 ,	2
600	The Role Erectile Dysfunction Plays in Cardiovascular Diseases. 2012 ,	
599	Priapism: pathophysiology and the role of the radiologist. 2012 , 85 Spec No 1, S79-85	29
598	Multiple sclerosis and sexual dysfunction. 2012 , 14, 530-5	49
597	Effects of male silkworm pupa powder on the erectile dysfunction by chronic ethanol consumption in rats. 2012 , 28, 83-90	17
596	The Role of PDE5 Inhibitors in the Treatment of Testicular Dysfunction. 2012 ,	1

595	Adenosine signaling: good or bad in erectile function?. 2012 , 32, 845-50	22
594	Endovascular therapy for vasculogenic erectile dysfunction. 2012 , 14, 193-202	16
593	Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. 2012 , 66, 813-820	7
592	Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 2012 , 9, 1174-81	2
591	Therapeutic effect of adipose-derived stem cells and BDNF-immobilized PLGA membrane in a rat model of cavernous nerve injury. 2012 , 9, 1968-79	35
590	Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. 2012 , 26, 141-7	36
589	Premature Ejaculation. 2013 ,	0
588	Secondary Premature Ejaculation. 2013 , 273-288	
587	From Diagnosis to Treatment: The Office Management of Premature Ejaculation. 2013 , 331-348	1
586	[Urological comorbidities in patients with rheumatoid arthritis : literature review]. 2013 , 72, 910-5	3
585	Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: application to pharmacokinetic study in rats. 2013 , 36, 457-63	8
584	Prevalence of internal pudendal artery disease in diabetic patients with erectile dysfunction and angiographically documented multi-vessel coronary artery disease. 2013 , 65, 87-91	2
583	Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. 2013 , 11, 222-9	24
582	[Erectile dysfunction]. 2013 , 23, 629-37	15
581	Office-based management of impotence and Peyronie's disease. 2013 , 40, 521-43	7
580	Association between erectile dysfunction and coronary artery disease and its severity. 2013 , 65, 180-6	15
579	The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. 2013 , 10, 1124-35	25
578	Stem-cell therapy for erectile dysfunction. 2013 , 13, 1585-97	34

577	Rapid-screening detection of acetildenafil, sildenafil and avanafil by ion mobility spectrometry. 2013 , 75, 153-7	24
576	The evaluation of sexual dysfunction in male patients with migraine and tension type headache. 2013 , 14, 46	11
575	Direct effects of vardenafil on the ureter: in vitro investigation and potential clinical applications of intraluminal administration. 2013 , 27, 1400-4	3
574	Is erectile dysfunction a reliable indicator of general health status in men?. 2013 , 11, 203-11	23
573	Recomendações Europeias para a prevenção da doença cardiovascular na prática clínica (versão de 2012). 2013 , 32, 553.e1-553.e77	4
572	Combined therapeutic effect of udenafil and adipose-derived stem cell (ADSC)/brain-derived neurotrophic factor (BDNF)-membrane system in a rat model of cavernous nerve injury. 2013 , 81, 1108.e7-14	39
571	Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial. 2013 , 189, 1006-13	20
570	Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. 2013 , 10, 1268-77	25
569	Preserved fertility despite erectile dysfunction in mice lacking the nitric oxide receptor. 2013 , 591, 491-502	6
568	The effect of periodontal treatment in improving erectile dysfunction: a randomized controlled trial. 2013 , 40, 148-54	22
567	Erectile Dysfunction: The Medical Treatment. 2013 , 12, 13-17	3
566	Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. 2013 , 82, 504-7	21
565	Neurologic Aspects of Sexual Function. 2013 , 351-363	0
564	Erectile dysfunction. 2013 , 381, 153-65	545
563	Primer of Geriatric Urology. 2013 ,	
562	Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction. 2013 , 28, 262-9	11
561	Characterization of the relaxant response to taurine in rat corpus cavernosum. 2013 , 91, 243-9	3
560	Improvement in symptoms of peripheral arterial disease with sildenafil therapy. 2013 , 58, e7-9	2

559	The impact of metabolic syndrome on retinal findings in patients with erectile dysfunction. 2013 , 39, 22-8		1
558	Male erectile dysfunction and microalbuminuria in adult nigerians with essential hypertension. 2013 , 5, 32-6		4
557	Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. 2013 , 10, e1001372		84
556	Udenafil: efficacy and tolerability in the management of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2013 , 5, 101-10	3.2	14
555	Improvement of erectile dysfunction after surgery for cervical disk herniation. 2013 , 74 Suppl 1, e89-91		
554	The relationship between resting heart rate variability and erectile tumescence among men with normal erectile function. 2013 , 10, 1961-8		8
553	Is there a relationship between chronic periodontitis and erectile dysfunction?. 2013 , 10, 838-43		27
552	The effect of long-term oral tadalafil treatment on corpus cavernosum function in an experimental spinal cord transection rat model. 2013 , 51, 663-7		4
551	Functional anatomy of the hypothalamicâ€”pituitaryâ€”gonadal axis and the male reproductive tract. 1-10		
550	Stimulators and activators of soluble guanylate cyclase: potential therapeutic indications. 2013 , 74-87		
549	A Quality Analysis of Randomized Controlled Trials about Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2013 , 31, 157-62	6.8	9
548	Penile rehabilitation following treatment for prostate cancer: an analysis of the current state of the art. 2009 , 3, 37-48		4
547	Validation of the International Index of Erectile Function (IIFE) for use in Brazil. 2013 , 101, 176-82		22
546	The GAY MEN Sex Studies: erectile dysfunction among Belgian gay men. 2013 , 6, 527-34		13
545	Sexual function in the aging male. 103-115		
544	Udenafil for the treatment of erectile dysfunction. 2014 , 10, 341-54		16
543	Hot-stage microscopy for determination of API particles in a formulated tablet. 2014 , 2014, 832452		3
542	Advances in Stem Cell Therapy for Erectile Dysfunction. 2014 , 2014, 1-20		5

541	Elective gangrene of the corpus spongiosum of idiopathic origin: A case report. 2014 , 8, E934-7	1
540	Associated factors and prevalence of erectile dysfunction in hemodialysis patients. 2014 , 40, 44-55	16
539	Pharmacological characterization of the relaxant effect induced by adrenomedullin in rat cavernosal smooth muscle. 2014 , 47, 876-85	
538	Adipose Derived Stem Cells for treatment of Lower Genitourinary Dysfunction. 2014 , 04,	
537	Metabolic Syndrome Impairs Erectile Function. 2014 , 141-180	
536	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2014 ,	
535	Abstracts of the 44th Annual Meeting of the International Continence Society (ICS) 20-24 October, 2014, Rio de Janeiro, Brazil. 2014 , 33, 631-1071	3
534	Men with diabetes may require more aggressive treatment for erectile dysfunction. 2014 , 26, 112-5	16
533	Peripheral atherosclerosis in patients with arterial erectile dysfunction. 2014 , 26, 55-60	18
532	Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. 2014 , 2014, 878670	51
531	Diagnosing erectile dysfunction could save your patient's life. 2014 , 8, S151-2	6
530	A proteomic analysis using an animal model for hyperlipidemia-related erectile dysfunction. 2014 , 64, 563-8	
529	Overview of the relevant literature on the possible role of acupuncture in treating male sexual dysfunction. 2014 , 32, 406-10	8
528	Altered expression of mitofusin 2 in penile tissues of diabetic rats. <i>Andrologia</i> , 2014 , 46, 522-8	2.4 7
527	Australian gay and bisexual men's use of erectile dysfunction medications during recent sexual encounters. 2014 , 11, 809-19	6
526	Urology at a Glance. 2014 ,	3
525	Erectile Dysfunction. 2014 , 6, 1-71	1
524	Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. 2014 , 21, 1263-7	19

523	Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse. 2014 , 111, E2731-40	41
522	The Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: 1-Year Follow-up. 2014 , 55, 112-9	15
521	Evaluation of vasculogenic erectile dysfunction: an angiographic atlas. 2014 , 25, S152	
520	The fundamentals of fiducial marker placement for image guided radiation therapy. 2014 , 25, S152	
519	Endovascular Treatment of Erectile Dysfunction. 2014 , 1237-1246	
518	Physiology of Erection. 2014 , 1-12	
517	Men's Sexual Health and Fertility. 2014 ,	7
516	Importancia de la rehabilitaci3n precoz de los cuerpos cavernosos tras prostatectom3a radical. 2014 , 12, 4-9	3
515	Radical Prostatectomy. 2014 ,	3
514	Prevalencia de comorbilidades y factores de riesgo asociados a disfunci3n er3ctil en pacientes hipertensos del Hospital Universitario del Caribe de Cartagena en 2013. 2014 , 23, 109-112	
513	Comparison between subcutaneous injection of basic fibroblast growth factor-hydrogel and intracavernous injection of adipose-derived stem cells in a rat model of cavernous nerve injury. 2014 , 84, 1248.e1-7	15
512	Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?. 2014 , 21, 856-64	22
511	Determination of grayanotoxins in honey by liquid chromatography tandem mass spectrometry using dilute-and-shoot sample preparation approach. 2014 , 62, 5485-91	14
510	Current Diagnosis and Management of Erectile Dysfunction. 2014 , 6, 164-176	41
509	Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. 2014 , 14, 52	21
508	Combined effects of brain-derived neurotrophic factor immobilized poly-lactic-co-glycolic acid membrane with human adipose-derived stem cells and basic fibroblast growth factor hydrogel on recovery of erectile dysfunction. 2014 , 20, 2446-54	25
507	Risk of rebleeding and death following bronchial artery embolization among patients with sarcoidosis. 2014 , 25, S151-S152	
506	Deciphering the role of endovascular techniques in the management of adult coarctation of the aorta: a systematic review. 2014 , 25, S152-S153	

505	Duration of hypertension and antihypertensive agents in correlation with the phases of female sexual response cycle. 2014 , 55 Suppl 1, S7-12	11
504	A2B Adenosine Receptor Agonist Improves Erectile Function in Diabetic Rats. 2015 , 237, 141-8	12
503	Neurology and sex. 2015 , 819-830	1
502	The Old Made New: Natural Compounds against Erectile Dysfunction. 2015 , 348, 607-14	22
501	Erectile Dysfunction is Associated with Subsequent Cardiovascular and Respiratory Mortality in Cohort of 1,436 Chinese Elderly Men. 2015 , 12, 1568-76	12
500	The risk of erectile dysfunction in chronic obstructive pulmonary disease: a population-based cohort study in Taiwan. 2015 , 94, e448	15
499	Endovascular treatment of vasculogenic erectile dysfunction. 2015 , 17, 40-3	12
498	PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction. 2015 , 87, 204-9	6
497	Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients. 2015 , 87, 210-3	12
496	Update on the Treatment of Erectile Dysfunction. 2015 ,	1
495	Clinical efficacy and safety of Vitaros [®] /Virirec [®] (Alprostadil cream) for the treatment of erectile dysfunction. 2015 , 82, 84-92	24
494	Role of Caffeine Intake on Erectile Dysfunction in US Men: Results from NHANES 2001-2004. 2014 , 10, e0123547	11
493	Sexual dysfunction in patients with spinal cord lesions. 2015 , 130, 225-45	24
492	Genital System. 2015 , 419-442	
491	Sexualmedizin in der Gynäkologie. 2015 ,	3
490	Anatomy and Physiology of Male Erectile Function. 2015 , 3-11	
489	Association between renal function, erectile function and coronary artery disease: detection with coronary angiography. 2015 , 56, 76-81	13
488	The Challenge of Erectile Dysfunction Management in the Young Man. 2015 , 16, 84	21

487	Low Quality of Life and Depressive Symptoms as an Independent Risk Factor for Erectile Dysfunction in Patients with Obstructive Sleep Apnea. 2015 , 12, 2168-77	8
486	Sexual Dysfunction in Patients with Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis. 2015 , 12, 1992-2003	36
485	The effect of pelvic floor muscle training on sexual function in men with lower urinary tract symptoms after stroke. 2015 , 22, 185-93	15
484	Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. 2015 , 116, 618-21	3
483	Acupuncture for erectile dysfunction: a systematic review protocol. 2015 , 5, e007040	7
482	Hemoglobinopathies and sleep--The road less traveled. 2015 , 24, 57-70	27
481	Clinical predictive factors of sildenafil response: a penile hemodynamic study. <i>Andrology</i> , 2015 , 3, 241-6 4.2	5
480	Novel therapeutic approach for neurogenic erectile dysfunction: effect of neurotrophic tyrosine kinase receptor type 1 monoclonal antibody. 2015 , 67, 716-26	28
479	[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus]. 2015 , 33, 40.e1-40.e16	6
478	Impaired vigilance is associated with erectile dysfunction in patients with sleep apnea. 2015 , 12, 405-15	10
477	Emerging drugs for the treatment of erectile dysfunction. 2015 , 20, 263-75	21
476	Erectile Dysfunction in the Elderly. 2015 , 4, 33-43	3
475	The role of physical activity in the treatment of erectile dysfunction. 2015 , 13, 115-119	1
474	N-acetylcysteine Ameliorates the Erectile Dysfunction Caused by Chronic Intermittent Hypoxia in Rats: Partly Involvement of Endoplasmic Reticulum Stress. 2015 , 86, 844.e7-844.e14	5
473	Effect of different beta blockers on penile vascular velocities in hypertensive males. 2015 , 46, 749-754	
472	Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model. 2015 , 85, 1214.e7-1214.e15	13
471	The evaluation of penile microvascular endothelial function using laser speckle contrast imaging in healthy volunteers. 2015 , 99, 96-101	5
470	8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors. 2015 , 25, 1431-5	10

469	Effects of insulin-like growth factor-1 on the relaxation responses of the cavernous smooth muscle from aged rats. 2015 , 49, 260-6	1
468	A discrepancy of penile hemodynamics during visual sexual stimulation observed by near-infrared spectroscopy. 2015 , 15, 11	7
467	[Conservative therapy of erectile dysfunction]. 2015 , 54, 668-75	5
466	Stem cell treatment of erectile dysfunction. 2015 , 82-83, 137-44	41
465	Cognitive Pearls in General Surgery. 2015 ,	
464	T-type Calcium Channels in Basic and Clinical Science. 2015 ,	0
463	To ED or not to ED--is erectile dysfunction in obstructive sleep apnea related to endothelial dysfunction?. 2015 , 20, 5-14	27
462	Penile histomorphometrical evaluation in hypertensive rats treated with sildenafil or enalapril alone or in combination: a comparison with normotensive and untreated hypertensive rats. 2015 , 12, 39-47	11
461	Effects of tadalafil-Type-V phosphodiesterase enzyme inhibitor-On rats with spinal trauma. 2015 , 29, 254-9	2
460	Erectile dysfunction: prevalence, risk factors and involvement of antihypertensive drugs intervention. 2016 , 15, 869	
459	Sexual Dysfunction in Men and Women. 2016 , 785-830	1
458	Short hairpin rna targeting insulin-like growth fator binding protein-3 restores the bioavailability of insulin-like growth factor-1 in diabetic rats. 2016 , 42, 139-45	2
457	Acupuncture for Erectile Dysfunction: A Systematic Review. 2016 , 2016, 2171923	17
456	Opportunities and challenges for direct C-H functionalization of piperazines. 2016 , 12, 702-15	23
455	Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. 2016 , 8, 123-31	11
454	The Current Status of Stem-Cell Therapy in Erectile Dysfunction: A Review. <i>World Journal of Men's Health</i> , 2016 , 34, 155-164	6.8 27
453	Postprostatectomy Erectile Dysfunction: A Review. <i>World Journal of Men's Health</i> , 2016 , 34, 73-88	6.8 35
452	The Effects of Adipose-Derived Stem Cells in a Rat Model of Tobacco-Associated Erectile Dysfunction. 2016 , 11, e0156725	13

451	Improvement of erectile dysfunction by the active peptide from <i>Urechis unicinctus</i> by high temperature/pressure and ultra - wave assisted lysis in Streptozotocin Induced Diabetic Rats. 2016 , 42, 825-37		5
450	Cross-sectional study of male sexual function in bariatric patients. 2016 , 11, 171-177		9
449	Management of Sexual Dysfunction in Men and Women. 2016 ,		6
448	Decrease of the insulin-like growth factor-1 bioavailability in spontaneously hypertensive rats with erectile dysfunction. <i>Andrologia</i> , 2016 , 48, 824-8	2.4	4
447	Erectogenic and Aphrodisiac Property of <i>Moringa oleifera</i> : Involvement of Soluble Epoxide Hydrolase Enzyme. 2016 , 30, 1119-27		12
446	Drug therapy for erectile dysfunction. 2016 , 172-193		
445	Erectile dysfunction and infertility. 2016 , 152-171		1
444	Anatomy of penile erection. 2016 , 22-29		1
443	Physiology of penile erection. 2016 , 14-21		1
442	Papel de las imágenes en el diagnóstico y tratamiento intravascular de la disfunción eréctil por fuga venosa en un paciente joven. 2016 , 25, 31-36		
441	Beneficial Effects of <i>Scutellaria baicalensis</i> on Penile Erection in Streptozotocin-Induced Diabetic Rats. 2016 , 44, 305-20		8
440	Sickle Cell Anemia. 2016 ,		4
439	Sac-1004, a Pseudo-Sugar Derivative of Cholesterol, Restores Erectile Function through Reconstruction of Nonleaky and Functional Cavernous Angiogenesis in the Streptozotocin Induced Diabetic Mouse. 2016 , 195, 1936-46		9
438	Erectile Dysfunction in Male Survivors of Childhood Cancer-A Report From the Childhood Cancer Survivor Study. 2016 , 13, 945-54		29
437	Novel Evidence-Based Classification of Cavernous Venous Occlusive Disease. 2016 , 196, 1223-7		7
436	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. 2016 , 17, 2281-2289		1
435	Primer of Geriatric Urology. 2016 ,		
434	Geriatric Sexuality. 2016 , 163-227		

433	Sexuality Following Hematopoietic Cell Transplantation. 2016 , 399-408		
432	Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. <i>Andrologia</i> , 2016 , 48, 20-8	2.4	11
431	Internal Pudental Artery Dysfunction in Diabetes Mellitus Is Mediated by NOX1-Derived ROS-, Nrf2-, and Rho Kinase-Dependent Mechanisms. 2016 , 68, 1056-64		25
430	Contemporary Treatment of Erectile Dysfunction. 2016 ,		2
429	Beneficial effect of PEDF-transfected ADSCs on erectile dysfunction in a streptozotocin-diabetic rat model. 2016 , 366, 623-637		11
428	Anatomy and Physiology of Erection, Ejaculation, and Orgasm. 2016 , 33-41		
427	Erectile dysfunction patients are more satisfied with penile prosthesis implantation compared with tadalafil and intracavernosal injection treatments. <i>Andrology</i> , 2016 , 4, 952-6	4.2	19
426	Erectile dysfunction. 2016 , 2, 16003		246
425	Normal Erectile Physiology. 2016 , 17-27		
424	Medical Management of Sexual Dysfunction in the Aging Male. 2016 , 32, 167-173		1
423	Avanafil - a further step to tailoring patient needs and expectations. 2016 , 9, 1171-81		5
422	Male Sexual Function and Smoking. 2016 , 4, 366-375		23
421	Risk factors for erectile dysfunction in patients with cardiovascular disease. 2016 , 44, 718-27		9
420	Salt-kneading: alternative sizing of active pharmaceutical ingredients?. 2016 , 21, 972-979		1
419	Mean platelet volume and platelet distribution as a diagnostic marker for penile vascular disease in patients with erectile dysfunction. 2016 , 14, 41-45		1
418	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). 2016 , 13, 465-88		110
417	The relationship between platelet-lymphocyte ratio and severity of erectile dysfunction. 2016 , 32, 91-5		7
416	Current Perspectives on Stem Cell Therapy for Erectile Dysfunction. 2016 , 4, 247-256		24

415	Hydrochlorothiazide Potentiates Contractile Activity of Mouse Cavernosal Smooth Muscle. 2016 , 4, e113-23		2
414	Sub-Coronal Inflatable Penile Prosthesis Placement With Modified No-Touch Technique: A Step-by-Step Approach With Outcomes. 2016 , 13, 270-6		30
413	Shengjing Capsule Improves Erectile Function Through Regulation of Nitric Oxide-induced Relaxation in Corpus Cavernosum Smooth Muscle in a Castrated Rat Model. 2016 , 91, 243.e7-243.e12		10
412	Erectile Dysfunction. 2016 , 333-352		
411	Drugs for Treatment of Erectile Dysfunction. 2016 , 783-800		
410	Prevalence of erectile dysfunction in a cohort of Italian hypertensive subjects. 2016 , 38, 143-9		4
409	The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. 2016 , 38, 357-61		2
408	Erectile dysfunction and diabetes: Association with the impairment of lipid metabolism and oxidative stress. 2016 , 49, 70-8		6
407	Combination Therapy Using Human Adipose-derived Stem Cells on the Cavernous Nerve and Low-energy Shockwaves on the Corpus Cavernosum in a Rat Model of Post-prostatectomy Erectile Dysfunction. 2016 , 88, 226.e1-9		43
406	Erectile Dysfunction and Sexual Hormone Levels in Men With Obstructive Sleep Apnea: Efficacy of Continuous Positive Airway Pressure. 2016 , 45, 235-40		26
405	Sexual Dysfunction. 2016 , 2154-2162.e3		1
404	Type 2 Diabetes. 2016 ,		2
403	Association of Urinary Phthalate Metabolites With Erectile Dysfunction in Racial and Ethnic Groups in the National Health and Nutrition Examination Survey 2001-2004. <i>American Journal of Men's Health</i> , 2017 , 11, 576-584	2.2	3
402	The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil. 2017 , 29, 82-85		3
401	Lower Urinary Tract Symptoms, Erectile Dysfunction, and Quality of Life in Poststroke Men: A Controlled Cross-Sectional Study. <i>American Journal of Men's Health</i> , 2017 , 11, 748-756	2.2	6
400	FTY720 Supplementation Partially Improves Erectile Dysfunction in Rats With Streptozotocin-Induced Type 1 Diabetes Through Inhibition of Endothelial Dysfunction and Corporal Fibrosis. 2017 , 14, 323-335		14
399	Long-term outcomes of AMS Spectra [®] penile prosthesis implantation and satisfaction rates. 2017 , 29, 184-188		16
398	Comprehensive assessment of cavernosography with 320-row dynamic volume CT versus conventional cavernosography in erectile dysfunction patients caused by venous leakage. 2017 , 37,		3

397	Usefulness of serum fetuin-A level as a marker of erectile dysfunction. 2017 , 29, 189-193		1
396	Adipose tissue-derived stem cell therapy for erectile dysfunction in rats: a systematic review and meta-analysis. 2017 , 49, 1127-1137		9
395	Differences in Cavernosal Artery Parameters According to Different Anatomic Sampling Locations During the Diagnosis of Vascular Erectile Dysfunction Using Duplex Ultrasound. 2017 , 105, 33-41		3
394	Effect of icariin in combination with daily sildenafil on penile atrophy and erectile dysfunction in a rat model of bilateral cavernous nerves injury. <i>Andrology</i> , 2017 , 5, 598-605	4.2	11
393	In vitro inhibition of phosphodiesterase-5 and arginase activities from rat penile tissue by two Nigerian herbs (<i>Hunteria umbellata</i> and <i>Anogeissus leiocarpus</i>). 2017 , 28, 393-401		32
392	Chromatographic fingerprinting as a strategy to identify regulated plants in illegal herbal supplements. 2017 , 164, 490-502		26
391	Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil. 2017 , 29, 96-100		3
390	Establishment of in vitro model of erectile dysfunction for the study of high-glucose-induced angiopathy and neuropathy. <i>Andrology</i> , 2017 , 5, 327-335	4.2	12
389	Surgical Techniques for Managing Post-prostatectomy Erectile Dysfunction. 2017 , 18, 90		20
388	Relationship between oxidative stress and erectile function. 2017 , 51, 924-931		5
387	Cardiovascular safety of phosphodiesterase inhibitors for treating erectile dysfunction in elderly men. 2017 ,		78
386	Association Between Opioid Use and Risk of Erectile Dysfunction: A Systematic Review and Meta-Analysis. 2017 , 14, 1209-1219		12
385	Effects of water extractable phytochemicals of mahogany (<i>Swietenia macrophylla</i>) and axlewood (<i>Anogeissus leiocarpus</i>) stem bark on some enzymes implicated in erectile dysfunction and type-2 diabetes. <i>Journal of Food Biochemistry</i> , 2017 , 41, e12430	3.3	4
384	Author Reply. 2017 , 105, 40-41		1
383	Delivery of intracavernosal therapies using needle-free injection devices. 2017 , 29, 225-228		5
382	Penile neurovascular structure revisited: immunohistochemical studies with three-dimensional reconstruction. <i>Andrology</i> , 2017 , 5, 964-970	4.2	5
381	Sexual intercourse as a new option in the medical expulsive therapy of distal ureteral stones in males: a prospective, randomized, controlled study. 2017 , 49, 1941-1946		9
380	Basaal wetenschappelijk bewijs voor de link tussen erectiele disfunctie en cardiometabole disfunctie. 2017 , 7, 102-110		

379	Characterization of age-related penile microvascular hemodynamic impairment using laser speckle contrast imaging: possible role of increased fibrogenesis. 2017 , 5, e13481	4
378	A state-of-art review of low intensity extracorporeal shock wave therapy and lithotripter machines for the treatment of erectile dysfunction. 2017 , 14, 929-934	28
377	Erectile Dysfunction in Young Men-A Review of the Prevalence and Risk Factors. 2017 , 5, 508-520	100
376	Prévalence et facteurs de risque de la dysfonction érectile chez les insuffisants rénaux chroniques. 2017 , 23, 331-337	1
375	Translating Penile Erectile Hydraulics to Clinical Application in Inflatable Penile Prosthesis Implant. 2017 , 9, 84-89	3
374	Chronic periodontitis and the risk of erectile dysfunction: a systematic review and meta-analysis. 2017 , 29, 43-48	11
373	Advances in Stem Cell Therapy. 2017 ,	3
372	The impact of surgery for trochanteric femur fracture on sexuality in men and their female partners. 2017 , 25, 2309499017742206	0
371	The Effect of Alcohol Administration on the Corpus Cavernosum. <i>World Journal of Men's Health</i> , 2017 , 35, 34-42	6.8 1
370	Involvement of DDAH/ADMA/NOS/cGMP and COX-2/PTGIS/cAMP Pathways in Human Tissue Kallikrein 1 Protecting Erectile Function in Aged Rats. 2017 , 12, e0170427	4
369	Aphrodisiac potentials of the ethanol extract of Aloe barbadensis Mill. root in male Wistar rats. 2017 , 17, 360	13
368	EFFECT OF EURYCOMA LONGIFOLIA ON SEXUAL BEHAVIOR IN SEXUALLY DYSFUNCTIONAL MALE: A SYSTEMATIC REVIEW. 2017 , 9, 46	0
367	Research in pharmacotherapy for erectile dysfunction. 2017 , 6, 207-215	17
366	Advances in the understanding of priapism. 2017 , 6, 199-206	20
365	Incontinence and Sexual Dysfunction. 2018 , 389-416	
364	The Magic Pill: The Branding of Impotence and the Positioning of Viagra as Its Solution through Edutainment. 2018 , 23, 281-290	5
363	An immunohistochemical and ultrastructural analysis of the retina in tadalafil (Cialis) treated rats. 2018 , 120, 312-322	1
362	Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products. 2018 , 10, 1315	4

361	Exercise training causes a partial improvement through increasing testosterone and eNOS for erectile function in middle-aged rats. 2018 , 108, 131-138		14
360	Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil. 2018 , 58, 905-912		5
359	Urological Survivorship Issues Among Adolescent Boys and Young Men Who Are Cancer Survivors. 2018 , 6, 396-409		9
358	Determination of Grayanotoxins from <i>Rhododendron brachycarpum</i> in Dietary Supplements and Homemade Wine by Liquid Chromatography-Quadrupole Time-of-Flight-Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry. 2018 , 66, 1935-1940		3
357	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. 2018 , 38, 1427-1436		16
356	Coffee Intake and Incidence of Erectile Dysfunction. 2018 , 187, 951-959		6
355	Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells Reduces Erectile Dysfunction Following Cavernous Nerve Injury in Rats. 2018 , 6, 49-57		16
354	Levels of uric acid in erectile dysfunction of different aetiology. <i>Aging Male</i> , 2018 , 21, 200-205	2.1	6
353	Effects of aqueous leaf extract of <i>Tridax procumbens</i> on contractile activity of corpus cavernosum in N-nitro-L-arginine methyl ester-induced hypertensive male rats. 2018 , 16, 51-56		3
352	Chronic periodontitis is associated with erectile dysfunction. A case-control study in european population. 2018 , 45, 791-798		9
351	Pericyte-Derived Dickkopf2 Regenerates Damaged Penile Neurovasculature Through an Angiotensin-1-Tie2 Pathway. 2018 , 67, 1149-1161		14
350	Erection-stimulating, anti-diabetic and antioxidant properties of <i>Hunteria umbellata</i> and <i>Cylicodiscus gabunensis</i> water extractable phytochemicals. 2017 , 15,		8
349	Spontaneous Regeneration of Nerve Fiber and Irreversibility of Corporal Smooth Muscle Fibrosis After Cavernous Nerve Crush Injury: Evidence From Serial Transmission Electron Microscopy and Intracavernous Pressure. 2018 , 118, 98-106		7
348	Sexual activity and cardiovascular disease, erectile dysfunction as a predictor of ischemic heart disease. 2018 , 60, e296-e305		0
347	Unreliability of the Duplex Scan in Diagnosing Corporeal Venous Occlusive Disease in Young Healthy Men With Erectile Deficiency. 2018 , 113, 91-98		7
346	Erectile Dysfunction Following Pelvic Fracture Urethral Injury. 2018 , 6, 114-123		23
345	Male Sexual Dysfunction. 2018 , 767-774		0
344	Erectile Dysfunction and Ischaemic Heart Disease. 2018 , 13, 98-103		16

343	Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction: Protocol for a systematic review. 2018 , 97, e12559	3
342	The 100 most influential manuscripts in andrology: a bibliometric analysis. 2018 , 28, 15	9
341	A gentle introduction to gasotransmitters with special reference to nitric oxide: biological and chemical implications. 2018 , 38, 193-220	16
340	Genetic variation in the locus is associated with erectile dysfunction. 2018 , 115, 11018-11023	14
339	Rapamycin Supplementation May Ameliorate Erectile Function in Rats With Streptozotocin-Induced Type 1 Diabetes by Inducing Autophagy and Inhibiting Apoptosis, Endothelial Dysfunction, and Corporal Fibrosis. 2018 , 15, 1246-1259	14
338	Efficient Promotion of Autophagy and Angiogenesis Using Mesenchymal Stem Cell Therapy Enhanced by the Low-Energy Shock Waves in the Treatment of Erectile Dysfunction. 2018 , 2018, 1302672	45
337	Erectile Dysfunction and Anejaculation in the Neurologic Patient. 2018 , 313-333	
336	Mad honey: uses, intoxicating/poisoning effects, diagnosis, and treatment.. 2018 , 8, 18635-18646	12
335	Does erectile dysfunction independently predict cardiovascular events? It's time to act on the evidence. 2018 , 25, 1307-1311	5
334	CT and MR Imaging Features of Artificial Urinary Sphincters, Penile Protheses, and Other Devices in the Male Lower Genitourinary Tract. 2018 , 38, 794-805	5
333	African crocus (<i>Curculigo pilosa</i>) and wonderful kola (<i>Buchholzia coriacea</i>) seeds modulate critical enzymes relevant to erectile dysfunction and oxidative stress. 2018 , 15,	13
332	Endocrine Disruptors in the Environment Affecting Erectile Function. 2018 , 503-512	
331	The Changes of MicroRNA Expression in the Corpus Cavernosum of a Rat Model With Cavernous Nerve Injury. 2018 , 15, 958-965	5
330	PnTx2-6 (or β -CNTX-Pn2a), a toxin from Phoneutria nigriventer spider venom, releases l-glutamate from rat brain synaptosomes involving Na and Ca channels and changes protein expression at the blood-brain barrier. 2018 , 150, 280-288	2
329	Investigation of Interactive Activity of Electro-Acupuncture on Pharmacokinetics of Sildenafil and Their Synergistic Effect on Penile Blood Flow in Rats. 2018 , 19,	5
328	Islet transplantation improved penile tissue fibrosis in a rat model of type 1 diabetes. 2018 , 18, 49	6
327	Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. 2018 , 30, 203-208	16
326	Icariside II ameliorates endothelial dysfunction by regulating the MAPK pathway via miR-126/SPRED1 in diabetic human cavernous endothelial cells. 2018 , 12, 1743-1751	10

325	Management of erectile dysfunction. 2018 , 545-554		
324	Effects of Endocrine-Disrupting Chemicals on Penile Tissue Development, Histoarchitecture, and Erectile Physiology. 2018 , 401-421		1
323	Penile Fibrogenesis Affecting Men's Reproductive and Sexual Health. 2018 , 423-437		
322	Role of Risk Factors Such as Smoking, Alcohol, and Substance Abuse on Sexual Health of Brazilian Men. 2018 , 475-482		
321	Evaluation of Sexual Dysfunction, Lower Urinary Tract Symptoms and Quality of Life in Men With Obstructive Sleep Apnea Syndrome and the Efficacy of Continuous Positive Airway Pressure Therapy. 2018 , 121, 86-92		19
320	Advantages and limitations of sleep-related erection and rigidity monitoring: a review. 2018 , 30, 192-201		7
319	Modulatory effect of some citrus (<i>Citrus limon</i> , <i>Citrus reticulata</i> , <i>Citrus maxima</i>) peels on monoamine oxidase, phosphodiesterase-5 and angiotensin-1 converting enzyme activities in rat heart homogenate. 2018 , 16,		1
318	Mental Health and Sexual Medicine: An Update. 2019 , 347-371		
317	Impotenz - Therapieoptionen 2019. 2019 , 21, 61-66		1
316	An update on the drug safety of treating erectile dysfunction. 2019 , 18, 965-975		6
315	Orange peels modulate antioxidant markers and key enzymes relevant to erection in the penile tissue of paroxetine-treated rats. <i>Andrologia</i> , 2019 , 51, e13371	2.4	7
314	Effect of Nut Consumption on Erectile and Sexual Function in Healthy Males: A Secondary Outcome Analysis of the FERTINUTS Randomized Controlled Trial. 2019 , 11,		12
313	Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis. 2019 , 39, 1527-1535		4
312	The application of spontaneous corpus cavernosum EMG to assess the status of cavernous smooth muscles, a preliminary study. 2019 , 17, 1-7		3
311	Sexual Dysfunction in Patients with Multiple Sclerosis from Argentina: What are the Differences Between Women and Men?. 2019 , 37, 521-539		5
310	The link between periodontitis and erectile dysfunction: a review. 2019 , 227, 599-603		6
309	Mesenchymal stem cell-derived exosomes ameliorate erection by reducing oxidative stress damage of corpus cavernosum in a rat model of artery injury. 2019 , 23, 7462-7473		10
308	Sexualstörungen bei Diabetes mellitus. 2019 , 15, 591-610		1

307	HPLC phenolic fingerprinting, antioxidant and anti-phosphodiesterase-5 properties of Rauwolfia vomitoria extract. 2019 , 30,		5
306	Extracorporeal Shock Waves Therapy Delivered by Aries Improves Erectile Dysfunction in Spontaneously Hypertensive Rats Through Penile Tissue Remodeling and Neovascularization. 2019 , 7, 441-450		6
305	S1P1 Gene Transfection Improves Erectile Function in Spontaneously Hypertensive Rats. 2019 , 133, 249.e1-249.e7		7
304	Elucidating Mechanisms of Long-Term Gasoline Vehicle Exhaust Exposure-Induced Erectile Dysfunction in a Rat Model. 2019 , 16, 155-167		6
303	Erectile Dysfunction Predicts Cardiovascular Events as an Independent Risk Factor: A Systematic Review and Meta-Analysis. 2019 , 16, 1005-1017		32
302	Effects of combined extracts of Lepidium meyenii and Allium tuberosum Rottl. on erectile dysfunction. 2019 , 19, 135		10
301	Advancements in Canadian Biomaterials Research in Neurotraumatic Diagnosis and Therapies. 2019 , 7, 336		1
300	Alkaloid extracts from Bitter leaf (<i>Vernonia amygdalina</i>) and Black nightshade (<i>Solanum nigrum</i>) inhibit phosphodiesterase-5, arginase activities and oxidative stress in rats penile tissue. <i>Journal of Food Biochemistry</i> , 2019 , 43, e12889	3.3	3
299	Neurocognitive impairment is associated with erectile dysfunction in cirrhotic patients. 2019 , 51, 850-855		4
298	<i>Ocimum gratissimum</i> Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats. 2019 , 19, 71		12
297	Inhibition of proNGF and p75 Pathway Restores Erectile Function Through Dual Angiogenic and Neurotrophic Effects in the Diabetic Mouse. 2019 , 16, 351-364		7
296	Administration of Adipose Derived Mesenchymal Stem Cells and Platelet Lysate in Erectile Dysfunction: A Single Center Pilot Study. 2019 , 6,		23
295	F-Fluoride Positron Emission Tomographic Imaging of Penile Arteries and Erectile Dysfunction. 2019 , 73, 1386-1394		8
294	Prospective Study on Sexual Dysfunction in Male Chinese Liver Transplant Recipients. <i>American Journal of Mens Health</i> , 2019 , 13, 1557988319835139	2.2	3
293	HIGHER GROWTH HORMONE LEVELS ARE ASSOCIATED WITH ERECTILE DYSFUNCTION IN MALE PATIENTS WITH ACROMEGALY. 2019 , 25, 562-571		7
292	Insulin resistance is an independent predictor of erectile dysfunction in patients with gout. 2019 , 34, 202-209		5
291	Sexual Dysfunction and Fertility in Neurogenic Lower Urinary Tract Dysfunction. 2019 , 457-478		7
290	Evaluation of some prostaglandins modulators on rat corpus cavernosum in-vitro: Is relaxation negatively affected by COX-inhibitors?. 2019 , 111, 1458-1466		7

289	Controversies in low intensity extracorporeal shockwave therapy for erectile dysfunction. 2019 , 31, 239-242		4
288	Synthesis and characterization of unsaturated diacyl and alkyl-acyl piperazine derivatives. <i>Turkish Journal of Chemistry</i> , 2019 , 43, 1656-1671	1	1
287	Embryonic stem cell-derived extracellular vesicle-mimetic nanovesicles rescue erectile function by enhancing penile neurovascular regeneration in the streptozotocin-induced diabetic mouse. 2019 , 9, 20072		8
286	Sexual function and cardiovascular disease: what the general cardiologist needs to know. 2019 , 105, 160-168		9
285	The Clinical Effects of Sildenafil for Erection in Patients after Kidney Transplantation: A Meta-Analysis. 2019 , 141, 1-9		4
284	The effect of diet on BPH, LUTS and ED. 2019 , 37, 1001-1005		7
283	Meta-analysis of the efficacy of sexual intercourse for distal ureteric stones. 2019 , 47, 497-504		2
282	Testosterone preserves endothelial function through regulation of S1P1/Akt/FOXO3a signalling pathway in the rat corpus cavernosum. <i>Andrologia</i> , 2019 , 51, e13173	2.4	5
281	Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials. 2019 , 37, 1061-1074		14
280	Sexual prowess from nature: A systematic review of medicinal plants used as aphrodisiacs and sexual dysfunction in sub-Saharan Africa. 2019 , 122, 342-359		13
279	Stem Cell Therapy for Erectile Dysfunction. 2019 , 7, 321-328		28
278	The association between cardiac resynchronization therapy response and sexual activity in patients with heart failure. 2020 , 61, 34-39		1
277	Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis. 2020 , 52, 205-217		4
276	Development of the human prepuce and its innervation. 2020 , 111, 22-40		8
275	Association between chronic obstructive pulmonary disease and risk of erectile dysfunction: a systematic review and meta-analysis. 2020 , 32, 159-166		6
274	The relationship between erectile dysfunction and the Atherogenic Index of Plasma. 2020 , 32, 462-468		3
273	Multiplicative effect of intrinsic and extrinsic motivation on academic performance: A longitudinal study of Chinese students. 2020 , 88, 584-595		16
272	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488		34

271	JTE-013 supplementation improves erectile dysfunction in rats with streptozotocin-induced type I diabetes through the inhibition of the rho-kinase pathway, fibrosis, and apoptosis. <i>Andrology</i> , 2020 , 8, 497-508	4.2	6
270	A modified wrinkle-free MoS film transfer method for large area high mobility field-effect transistor. 2020 , 31, 055707		12
269	Metabolic syndrome is not associated with erectile dysfunction in apparently healthy men. 2020 , 14, 460-463		5
268	Le priapisme art ^h riel. 2020 , 30, F77-F80		1
267	Exosomes derived from smooth muscle cells ameliorate diabetes-induced erectile dysfunction by inhibiting fibrosis and modulating the NO/cGMP pathway. 2020 , 24, 13289-13302		7
266	A prospective study of the effect of antihypertensive medications on the sexual functions of hypertensive adult male patients. 2020 , 6, FSO479		2
265	Erectile Dysfunction After Surgical Treatment of Lung Cancer: Real-World Evidence. 2020 , 12, 977-987		0
264	The relationships between bariatric surgery and sexual function: current evidence based medicine. 2020 , 20, 150		0
263	Risk factors of erectile dysfunction among diabetes patients in Africa: A systematic review and meta-analysis. 2020 , 21, 100232		1
262	Comprehensive Analysis of lncRNA Expression Pattern and lncRNA-miRNA-mRNA Network in a Rat Model With Cavernous Nerve Injury Erectile Dysfunction. 2020 , 17, 1603-1617		5
261	Urology and nephrology. 2020 , 207-255		
260	Potential activity of <i>Aframomum daniellii</i> (Zingiberaceae) dry seeds: A case study of its action mechanism on the Wistar rat strain with testicular deficiency. 2020 , 131, 110759		2
259	Self-Nanoemulsifying System Loaded with Sildenafil Citrate and Incorporated within Oral Lyophilized Flash Tablets: Preparation, Optimization, and In Vivo Evaluation. 2020 , 12,		8
258	Obstructive Sleep Apnea and Testosterone Replacement Therapy. 2020 , 1, 10-14		1
257	Management of male sexual dysfunction after cancer treatment. 2020 ,		3
256	Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature. <i>Andrology</i> , 2020 , 8, 1660-1673	4.2	4
255	Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review. 2020 , 9,		20
254	The Role of Testosterone in Amplifying the Effect of a Phosphodiesterase Type 5 Inhibitor After Pelvic Irradiation. 2020 , 17, 1268-1279		1

253	Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. <i>Aging Male</i> , 2020 , 23, 161-167	2.1	1
252	The Combined Use of Stem Cells and Platelet Lysate Plasma for the Treatment of Erectile Dysfunction: A Pilot Study-6 Months Results. 2020 , 7,		7
251	Human Tissue Kallikrein 1 Improves Erectile Dysfunction of Streptozotocin-Induced Diabetic Rats by Inhibition of Excessive Oxidative Stress and Activation of the PI3K/AKT/eNOS Pathway. 2020 , 2020, 6834236		3
250	Prevalence of Erectile Dysfunction in Patients with Diabetes Mellitus and Its Association with Body Mass Index and Glycated Hemoglobin in Africa: A Systematic Review and Meta-Analysis. 2020 , 2020, 5148370		14
249	Pharmacology and perspectives in erectile dysfunction in man. 2020 , 208, 107493		17
248	Hypoactive sexual desire disorder (HSDD) is not "female erectile dysfunction (ED)": challenges with the characterization of HSDD in women based on a systematic literature review. 2020 , 36, 1069-1080		1
247	Sonography of the penis/erectile dysfunction. 2020 , 45, 1973-1989		4
246	Evaluation of the potential aphrodisiac activity of sesquiterpenoids from roots of <i>Ferula huber-morathii</i> Peñen in male rats. 2020 , 257, 112868		3
245	Erectile Dysfunction Resistant to Medical Treatment Caused by Cavernovenous Leakage: An Innovative Surgical Approach Combining Pre-operative Work Up, Embolisation, and Open Surgery. 2021 , 61, 510-517		3
244	Accurately Assessing Gay Men's Erectile Functioning: A Critique of the International Index of Erectile Function (IIEF) Use with Gay Men. 2021 , 58, 589-598		2
243	Enzymatic preparation of <i>Crassostrea</i> oyster peptides and their promoting effect on male hormone production. 2021 , 264, 113382		7
242	Exosomes derived from miR-301a-3p-overexpressing adipose-derived mesenchymal stem cells reverse hypoxia-induced erectile dysfunction in rat models. 2021 , 12, 87		5
241	Male Sexual and Reproductive Health. 2021 ,		0
240	Post-Stroke Sexual Disorders and Its Real-Life Experience within Couples in Brazzaville. 2021 , 11, 22-33		0
239	Efficacy of penile low-intensity shockwave treatment for erectile dysfunction: correlation with the severity of cavernous artery disease. 2021 , 23, 462-467		1
238	Non-Acetolysed Pollen Analysis of Mad Honey from the Himalayas, Nepal. 2021 , 98, 63-67		
237	Erectile Dysfunction in a Sample of Sexually Active Young Adult Men from a U.S. Cohort: Demographic, Metabolic and Mental Health Correlates. 2021 , 205, 539-544		9
236	Percutaneous Treatment of Venous Erectile Dysfunction. 2020 , 7, 626943		0

- 235 Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review). **2021**, 21, 320
- 234 Penile Length Measurement: Methodological Challenges and Recommendations, a Systematic Review. **2021**, 18, 433-439 1
- 233 Evaluation of erectile dysfunction in the ageing men using colour Doppler sonography. **2021**, 27,
- 232 Sildenafil citrate in healthy and diseased hearts. **2021**, 6, 033-039 0
- 231 Anatomy, Pathophysiology, Molecular Mechanisms, and Clinical Management of Erectile Dysfunction in Patients Affected by Coronary Artery Disease: A Review. **2021**, 9, 4
- 230 Medicolegal evaluation of the erectile function of patients referred from the Forensic Medicine Authority of the Ministry of Justice in Upper Egypt. **2021**, 75, e14252
- 229 A Computational Model of the Pudendal Nerve for the Bioelectronic Treatment of Sexual Dysfunctions. **2021**,
- 228 The Relationship Between Gensini Score and Erectile Dysfunction in Patients with Chronic Coronary Syndrome. **2021**, 9, 100376
- 227 Penile arterial communications and severity of erectile dysfunction, evaluation by color Doppler ultrasound. 205141582110222
- 226 Erectile Dysfunction and Partner-Directed Behaviors in Romantic Relationships: The Mediating Role of Suspicious Jealousy. **2021**, 1-12 2
- 225 A Mid-to-Long Term Comprehensive Evaluation of Psychological Distress and Erectile Function in COVID-19 Recovered Patients. **2021**, 18, 1863-1871 2
- 224 Efficacy and safety of aildenafil citrate in Chinese men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled crossover trial. **2021**, 10, 3358-3367 0
- 223 A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction. **2021**, 5, ytab244 1
- 222 Non-invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea. **2021**, 9, CD013169 1
- 221 The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews. **2021**, 12, 735708 3
- 220 [Erectile dysfunction in patients with cardiovascular disease and the potential influence of genetic markers]. **2021**, 19, 217-223
- 219 Stem Cell and Gene-Based Therapy for Erectile Dysfunction: Current Status and Future Needs. **2021**, 48, 611-619 3
- 218 Sexual dysfunctions. **2021**, 235-285

217	Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. 2021 ,	2
216	Introduction to erectile dysfunction. 2021 , 19-42	
215	Non-invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea.	1
214	Treatment of Erectile Dysfunction. 2006 , 284-290	1
213	Geriatric Sexuality. 2013 , 143-200	1
212	Physiology of Erection and Causes of Erectile Dysfunction. 2004 , 1-18	1
211	Cardiovascular Safety of Phosphodiesterase-5 Inhibitors. 2004 , 139-161	1
210	Genitourinary Complications. 2007 , 453-472	2
209	Normal Erectile Physiology. 2011 , 11-22	2
208	Erectile Dysfunction: Pharmacological Therapy. 2011 , 675-696	1
207	Erectile Dysfunction: Etiology and Risk Factors. 2016 , 57-70	2
206	Sex and Chronic Physical Illness. 2017 , 479-506	2
205	Physiology of Penile Erection and Pathophysiology of Erectile Dysfunction. 2008 , 15-20	1
204	Erectile dysfunction and lower urinary tract. 2009 , 507-31	12
203	Associations between body mass index, waist circumference and erectile dysfunction: a systematic review and META-analysis. 2020 , 21, 657-666	12
202	The reproductive system. 2007 , 445-460	1
201	Physiology of Penile Erection and Pathophysiology of Erectile Dysfunction. 2012 , 688-720.e11	11
200	Peyronie's Disease. 2012 , 792-809.e4	3

199	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
198	Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment. 2011 , 13, 851-5		6
197	Impaired flow-mediated vasodilatation in Asian Indians with erectile dysfunction. 2013 , 15, 652-7		4
196	Penile prosthesis implantation in Chinese patients with severe erectile dysfunction: 10-year experience. 2013 , 15, 658-61		14
195	Effects of heart rate reduction with ivabradine on the international index of erectile function (IIEF-5) in patients with heart failure. <i>Aging Male</i> , 2018 , 21, 93-98	2.1	8
194	Protease inhibitors and erectile dysfunction. 2001 , 15, 2331-3		34
193	VASCULAR ENDOTHELIAL GROWTH FACTOR PROMOTES PROLIFERATION AND MIGRATION OF CAVERNOUS SMOOTH MUSCLE CELLS. 2001 , 354-360		1
192	INCIDENCE OF ERECTILE DYSFUNCTION IN ITALIAN MEN WITH DIABETES. 2001 , 1368-1371		5
191	The Relationship Of Serum Testosterone To Erectile Function In Normal Aging Men. 2002 , 1745-1748		5
190	Nitric Oxide Independent Activation of Guanylate Cyclase by YC-1 Causes Erectile Responses in the Rat. 2002 , 2276-2281		1
189	Male sexual dysfunction associated with antiretroviral therapy. 2002 , 30, 27-32		52
188	Role of identified noncoding RNA in erectile dysfunction. <i>Andrologia</i> , 2020 , 52, e13596	2.4	4
187	Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. 2008 , 118, 1491-501		118
186	Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by <i>Plasmodium berghei</i> ANKA. 2012 , 7, e32048		28
185	Long-term treatment of clonidine, atenolol, amlodipine and dihydrochlorothiazide, but not enalapril, impairs the sexual function in male spontaneously hypertensive rats. 2015 , 10, e0116155		5
184	Sympathetic Hyperactivity, Increased Tyrosine Hydroxylase and Exaggerated Corpus Cavernosum Relaxations Associated with Oxidative Stress Plays a Major Role in the Penis Dysfunction in Townes Sickle Cell Mouse. 2016 , 11, e0166291		9
183	Compatibility Studies of Sildenafil with Different Excipients by Using TGA, DSC, XRD and FTIR. 2019 , 15, 401-407		3
182	Effects of metformin on endothelial health and erectile dysfunction. 2017 , 6, 556-565		13

181	Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives. 2019 , 25, 2741-2771	16
180	Erectile dysfunction: new technologies and approaches in diagnostics and treatment. 2020 , 8, 78-92	7
179	A Case Report of Cyanopsia after Taking Sildenafil. 2020 , 30, 59-64	1
178	Erectile dysfunction in patients with liver disease related to chronic hepatitis B. 2015 , 21, 352-7	11
177	Positive Correlation between Left Hemisphere Lesion and Erectile Dysfunction in Post-Stroke Patients. 2019 , 7, 363-368	6
176	The role of statins in erectile dysfunction: a systematic review and meta-analysis. 2014 , 16, 461-6	39
175	Clinical significance of erectile dysfunction developing after acute coronary event: exception to the rule or confirmation of the artery size hypothesis?. 2015 , 17, 21-5	9
174	A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. 2016 , 18, 60-5	3
173	The application of color Doppler flow imaging in the diagnosis and therapeutic effect evaluation of erectile dysfunction. 2016 , 18, 118-22	11
172	Penile erectile dysfunction after brachial plexus root avulsion injury in rats. 2014 , 9, 1839-43	3
171	Psychosexual disorders and dermatologists. 2016 , 7, 149-58	6
170	Prevalence of, and risk factors for erectile dysfunction in male type 2 diabetic outpatient attendees in Enugu, South East Nigeria. 2018 , 17, 215-220	5
169	Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. 2020 , 22, 379-382	7
168	Lipoxin A4 improves erectile dysfunction in rats with type I diabetes by inhibiting oxidative stress and corporal fibrosis. 2018 , 20, 166-172	19
167	Thorax Computed Tomography Findings in Patients with Erectile Dysfunction. 2017 , 7, 25	1
166	Fingerroot, and its Aphrodisiac Activity. 2017 , 11, 27-30	15
165	Efficacy and safety of an herbal formula (KBMSI-2) in the treatment of erectile dysfunction: A preliminary clinical study. 2019 , 60, 275-284	6
164	Cell phone usage and erectile function. 2013 , 66, 75-7	7

163	Sleep, Sleep Disorders, and Sexual Dysfunction. <i>World Journal of Men's Health</i> , 2019 , 37, 261-275	6.8	31
162	A Case of Sudden Sensorineural Hearing Loss Associated with Phosphodiesterase Type 5 Inhibitors. 2017 , 110, 505-509		1
161	Liver transplant may improve erectile function in patients with benign end-stage liver disease: single-center Chinese experience. 2013 , 11, 332-8		5
160	Testosterone improves erectile function through inhibition of reactive oxygen species generation in castrated rats. 2016 , 4, e2000		28
159	Can Erectile Dysfunction in Young Patients Serve as a Surrogate Marker for Coronary Artery Disease?. 2015 , 9, PC01-3		4
158	Chemical Communication Between Cells. 2001 , 1741-1829		
157	Psychosoziale Probleme. 2001 , 387-399		
156	PENILE ANATOMY UNDER THE PUBIC ARCH: RECONSTRUCTIVE IMPLICATIONS. 2001 , 225-230		1
155	Andrologische Störungen. 2002 , 1279-1307		
154	Entmarkungskrankheiten. 2002 , 479-500		
153	An Extract From the Bark of <i>Aspidosperma Quebracho Blanco</i> Binds to Human Penile α -Adrenoceptors. 2002 , 160-163		
152	Diagnostic Steps In The Evaluation Of Patients With Erectile Dysfunction. 2002 , 615-620		1
151	Diagnosis and Therapy of Erectile Dysfunction Following Radical Prostatectomy. 2003 , 211-220		
150	Andrologie. 2003 , 487-493		
149	Sexualität. 2004 , 259-298		
148	Primary Care Issues in the Management of Erectile Dysfunction. 2004 , 229-233		
147	Gene Therapy for Erectile Dysfunction. 2004 , 183-190		
146	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181		

- 145 A Psychiatric Perspective on Psychogenic Erectile Dysfunction. **2004**, 73-86
- 144 Erectile Dysfunction. **2004**, 24-28
- 143 External Lyogel Formulation of Prostaglandin E1 Ethyl Ester. **2004**, 34, 107-114
- 142 Erectile dysfunction in the aging man: current options for treatment. **2006**, 2, 71-86 ○
- 141 Erectile Dysfunction and Cardiovascular Disease. **2007**, 2791-2801
- 140 Section II: Pharmacological Interventions. **2007**, 389-408
- 139 Diabetic Peripheral Neuropathy and Sexual Dysfunction. **2007**, 277-312
- 138 Aspectos neurológicos de la función sexual. **2008**, 361-370
- 137 Association between Erectile Dysfunction and Metabolic Syndrome in Aging Men: Hallym Aging Study. **2009**, 50, 682 1
- 136 Andrology. **2009**, 1177-1189
- 135 Erectile Function Preservation and Rehabilitation. **2009**, 139-162
- 134 Imaging del pene. **2010**, 269-283
- 133 Management of Erectile Dysfunction. 134-145
- 132 Animal Models for the Study of Erectile Function and Dysfunction. **2011**, 1-10
- 131 Oral Therapy for Erectile Dysfunction. **2011**, 93-106 ○
- 130 Erectile Dysfunction: Prevalence and Pathophysiology. **2011**, 183-193
- 129 Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie's Disease. **2011**, 373-383 1
- 128 Erectile Function Preservation for Men with Cancer. **2011**, 657-673

127 Pelvic Surgery for Urological Cancers. **2011**, 477-488

126 Medical Treatments for Sexual Problems in Women. **2011**, 627-641

1

125 SELECTED REFERENCES. **2011**, 307

124 Dysfonction Érectile et Médecine Vasculaire. **2011**, 587-599

123 Efficacy and safety of vardenafil in men with diabetes and erectile dysfunction.

122 Introduction. **2012**, 1001-1004

121 Men's Health. **2012**, 967-979

120 Urinary Tract Disorders. **2012**, 899-927

119 Literatur. **2012**, 307

118 References. 577-616

117 Erectile Dysfunction. **2013**, 973-995

116 Postoperative Management: Erectile Function. **2014**, 167-188

115 Erectile Dysfunction. **2014**, 263-267

114 Geriatric Sexuality. **2014**, 377-415

113 Diabetische Folgeerkrankungen. **2014**, 239-296

112 Erectile Dysfunction and Infertility. **2014**, 89-117

111 Regulation of T-Type Ca²⁺ Channels by Intercellular and Intracellular Signals. **2015**, 19-35

110 Notes. **2015**, 229-250

- 109 The Birth of Nanke (Men's Medicine). **2015**, 29-50
- 108 Bushen (Nourishing the Kidney), Shugan (Smoothing out the Liver), or Taking the Great Brother (Viagra). **2015**, 166-197
- 107 Sexual Repression. **2015**, 51-70
- 106 The Loss of Jing (Seminal Essence) and the Revival of Yangsheng (the Cultivation of Life). **2015**, 135-165
- 105 Impotence, Family, and Women. **2015**, 101-131
- 104 References. **2015**, 251-276
- 103 One Thousand Bodies of Impotence. **2015**, 71-100
- 102 Introduction. **2015**, 1-26
- 101 Conclusion. **2015**, 221-228
- 100 Potency Is Fullness of Life. **2015**, 198-220
- 99 Endovascular Approaches to Penile Arterial Revascularization for Vasculogenic Erectile Dysfunction. **2016**, 221-240 1
- 98 Impact of Prostate Cancer Treatments on Sexual Health. **2016**, 585-595 1
- 97 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2016**, 83-115
- 96 Role of Oxidative Stress in Erectile Dysfunction After Prostate Cancer Therapy. **2016**, 499-508
- 95 Effects of Lifestyle Changes and Testosterone Therapy on Erectile Function. **2016**, 101-130
- 94 Priapism in Sickle Cell Disease: New Aspects of Pathophysiology. **2016**, 269-283
- 93 Urologic and Clinical Evaluation of the Male with Erectile Dysfunction. **2016**, 43-52
- 92 Medications, natural substances, and dietary supplements in treating sexual dysfunctions: a sexologist's perspective. **2016**, 13, 188-190

- 91 Stem Cell Therapy and Tissue Engineering in Urogenital Diseases. **2017**, 197-223
- 90 Treating Erectile Dysfunctions. **2017**, 201-225
- 89 Association between coronary heart disease and erectile dysfunction in Chinese Han population. **2017**, 8, 55562-55566 0
- 88 Urogenital Symptoms in Neurologic Patients. **2017**, 23, 533-552 1
- 87 Erektionsstörungen. **2018**, 289-314 0
- 86 A Case of Sudden Sensorineural Hearing Loss Associated with Phosphodiesterase Type 5 Inhibitors. **2018**, 152, 6-7
- 85 An overlooked issue: sexual dysfunctions in men addicted to alcohol. **2018**, 19, 112-124 1
- 84 Current options and trends in treating erectile dysfunction. **2018**, 19, 127-132
- 83 Hiperlipidemi ve Eretil Disfonksiyon. 0
- 82 Obesity and Men's Health. **2019**, 149-168
- 81 Absence of Nocturnal Penile Tumescence: An Earlier Sign of Erectile Dysfunction and Its Linked Comorbid Conditions. **2020**, 3, 72-76
- 80 Modern Strategies for the Surgical Treatment of Priapism. **2020**, 523-545
- 79 Prevalence of erectile dysfunction patients with diabetes mellitus and its association with body mass index and glycated hemoglobin in Africa: a systematic review and meta-analysis.
- 78 Pharmacological management of male sexual dysfunction. **2020**, 63, 356-364
- 77 Physiology and Pharmacology of the Prostate. **2020**, 127-150 1
- 76 Herbal aphrodisiac biomolecules in the management of male reproductive and sexual problems: connecting nature with clinics. **2022**, 591-611
- 75 PDE5i therapy. **2020**, 131-140
- 74 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2020**, 85-118

- 73 Mitochondrial ATP synthase regulates corpus cavernosum smooth muscle cell function and. **2020**, 19, 3497-3504
- 72 Erectile Dysfunction. **2006**, 363-376
- 71 Sexual Dysfunction and Cardiovascular Risk – Links and Solutions. **2009**, 199-215
- 70 Normal Anatomy and Physiology. **2006**, 1-45 1
- 69 Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. **2004**, 1, 185-196
- 68 US of the Postoperative Penis. **2008**, 133-146
- 67 Supportive Treatment. **2008**, 204-292
- 66 A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure. **2020**, 15, e0242006 1
- 65 Evaluation of the Antioxidant Activity of Some Plants Used in the Management of Erectile Dysfunction by the BWA Community in Mali. **2020**, 10, 57-61
- 64 Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. **2004**, 6, 121-7 15
- 63 Future strategies for treating erectile dysfunction. **2002**, 4 Suppl 3, S48-53 1
- 62 Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. **2003**, 5 Suppl 7, S9-S20 1
- 61 Impact of phosphodiesterase type 5 inhibitors on endothelial function. **2008**, 10, 26-30 6
- 60 Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. *Mayo Clinic Proceedings*, **2009**, 84, 139-48 6.4 29
- 59 Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions. *Canadian Journal of Plastic Surgery*, **2010**, 18, e5-9 2
- 58 Evaluations of erectile dysfunction before and after on-pump coronary artery bypass graft surgery. *Caspian Journal of Internal Medicine*, **2014**, 5, 209-12 1 2
- 57 The relation between erectile dysfunction and extent of coronary artery disease in the patients with stable coronary artery disease. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 21295-302 6
- 56 Synthesis and characterization of piperazine-substituted dihydrofuran derivatives via Mn(OAc) mediated radical cyclizations. *Turkish Journal of Chemistry*, **2020**, 44, 1303-1313 1

55	Beneficial Extracardiac Effects of Cardiovascular Medications. <i>Current Cardiology Reviews</i> , 2021 ,	2.4	1
54	Germanium-Titanium-IPolymer Composites as Functional Textiles for Clinical Strategy to Evaluate Blood Circulation Improvement and Sexual Satisfaction. <i>Polymers</i> , 2021 , 13,	4.5	0
53	Endovascular therapy for erectile dysfunction: current knowledge and future perspectives. <i>Minerva Cardiology and Angiology</i> , 2021 , 69, 579-595	2.4	3
52	Lithium and Erectile Dysfunction: An Overview.. <i>Cells</i> , 2022 , 11,	7.9	1
51	Association between sarcopenia and erectile dysfunction in older males.. <i>Archives of Gerontology and Geriatrics</i> , 2021 , 99, 104619	4	
50	Synthesis and characterization of piperazine-substituted dihydrofuran derivatives viaMn(OAc) ₃ mediated radical cyclizations. <i>Turkish Journal of Chemistry</i> , 2020 , 44, 1303-1313	1	1
49	Erektionsstörungen. 2021 , 251-271		
48	Role of shear wave elastography (SWE) in erectile dysfunction patients for evaluation of daily tadalafil treatment outcome.. <i>Andrologia</i> , 2022 , e14359	2.4	
47	iTRAQ-based identification of differentially expressed proteins in ED rat model induced by cold stress combined with environmental oestrogen.. <i>Andrologia</i> , 2022 , e14382	2.4	1
46	Influence of lemon (<i>Citrus limon</i>) and lime (<i>Citrus aurantifolia</i>) juices on the erectogenic properties of sildenafil in rats with L-NAME-induced erectile dysfunction.. <i>Journal of Food Biochemistry</i> , 2022 , e14074	3.3	1
45	Potential Effect of the Circadian Clock on Erectile Dysfunction.. 2022 , 13, 8-23		0
44	Telerehabilitation for Treatment of Sexual Concerns. 2022 , 251-261		
43	Effect of liver cirrhosis on erectile function in rats: A study combining bioinformatics analysis and experimental research.. <i>Andrologia</i> , 2021 , e14352	2.4	
42	Evaluation of the antioxidant potential of the mad honey collected from the black sea region in Turkey. <i>Journal of Advances in VetBio Science and Techniques</i> ,	0.1	
41	Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials.. <i>Therapeutic Advances in Urology</i> , 2022 , 14, 17562872221086999	3.2	2
40	Priapism caused by partial deficiency of tetrahydrobiopterin through hypofunction of the sympathetic neurons in sepiapterin reductase gene-disrupted mice.. <i>Journal of Inherited Metabolic Disease</i> , 2022 ,	5.4	0
39	Accurate and time-saving, two-step intracavernosal injection procedure to diagnose psychological erectile dysfunction.. <i>Andrology</i> , 2022 ,	4.2	
38	Wearable E-Textile and CNT Sensor Wireless Measurement System for Real-Time Penile Erection Monitoring.. <i>Sensors</i> , 2021 , 22,	3.8	0

37	Associations of impaired grip strength and gait function with the severity of erectile dysfunction in men undergoing dialysis: a cross-sectional study.. <i>Aging Male</i> , 2022 , 25, 1-7	2.1	
36	Association Between Chronic Periodontal Disease and Erectile Dysfunction: A Case-Control Study.. <i>American Journal of Men's Health</i> , 2022 , 16, 15579883221084798	2.2	
35	Treatment of Erectile Dysfunction. 2006 , 284-290		
34	Evaluation of endothelial dysfunction with cardio-ankle vascular index measurements in patients with erectile dysfunction.. <i>Andrology</i> , 2022 ,	4.2	0
33	Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease.. <i>American Journal of Clinical and Experimental Urology</i> , 2022 , 10, 25-30	1.6	
32	Human Papillomavirus Infection and the Risk of Erectile Dysfunction: A Nationwide Population-Based Matched Cohort Study. <i>Journal of Personalized Medicine</i> , 2022 , 12, 699	3.6	2
31	Cardiovascular/Stroke Risk Assessment in Patients with Erectile DysfunctionâA Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review. <i>Diagnostics</i> , 2022 , 12, 1249	3.8	0
30	Erectile Dysfunction and Obstructive Sleep Apnea: A Review. <i>Frontiers in Psychiatry</i> , 2022 , 13,	5	0
29	Genetic Evidence Supporting a Causal Role of Snoring in Erectile Dysfunction. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7	0
28	Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study. <i>World Journal of Men's Health</i> , 40,	6.8	
27	Non-Coding RNAs: New Dawn for Diabetes Mellitus Induced Erectile Dysfunction. <i>Frontiers in Molecular Biosciences</i> , 9,	5.6	0
26	Selecting an Individualized Treatment Approach: The Predictive Value of Erotic Stimulation and Nocturnal Erections for Efficacy of Tadalafil and Cure in Patients With Erectile Dysfunction. <i>Frontiers in Endocrinology</i> , 13,	5.7	
25	NLRP3 downregulation enhances engraftment and functionality of adipose-derived stem cells to alleviate erectile dysfunction in diabetic rats. <i>Frontiers in Endocrinology</i> , 13,	5.7	1
24	MYPT1 reduction is a pathogenic factor of erectile dysfunction. <i>Communications Biology</i> , 2022 , 5,	6.7	0
23	Evaluation of the Combined Effects of Turkish Mad Honey and 5-Fluorouracil in Colon Cancer Model in Rats.		
22	Comparison of three different tadalafil regimens for erectile dysfunction treatment in patients with diabetes mellitus microvascular complications.		
21	Sexual dysfunctions and their treatment in liver diseases. 2022 , 14, 1530-1540		
20	Extracellular vesicles from human urine-derived stem cells merged in hyaluronic acid ameliorate erectile dysfunction in type 2 diabetic rats by glans administration.		0

- 19 PDE5 inhibitors and male reproduction: Is there a place for PDE5 inhibitors in infertility clinics or andrology laboratories?. 1
- 18 Correlation analysis of carotid artery intima-media thickness, serum 25(OH)D and men with erectile dysfunction. 13, 0
- 17 Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. **2022**, 10, 764-781 0
- 16 Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. **2022**, 205, 115256 0
- 15 Drug reprofiling history and potential therapies against Parkinson's disease. 13, 0
- 14 FDA approved fused pyrimidine-based drugs. **2023**, 13-38 0
- 13 Effects of *Mirabilis jalapa* L. root extract and sildenafil on paroxetine-induced sexual dysfunction in male rats and characterization of its phytoconstituents by UPLC-MS. **2023**, 152, 240-246 0
- 12 Influence of lauric acid on the relaxation of corpus cavernosum in streptozotocin-induced diabetic male Wistar rats. **2022**, 8, 0
- 11 Anabolic-androgenic steroids: How do they work and what are the risks?. 13, 0
- 10 Leech-Centipede Granules Suppress EndMT to Improve Erectile Dysfunction in Rats with Diabetes Mellitus via TGF- β /Smad Pathway. **2023**, 29, 28-36 0
- 9 Erectile Dysfunction Caused by Cavernous Leakage. 0
- 8 The Spanish Version of the International Index of Erectile Function: Adaptation and Validation. **2023**, 20, 1830 0
- 7 Effect of angiotensin receptor-neprilysin inhibitor treatment on erectile dysfunction in heart failure with a reduced ejection fraction. 99-104 0
- 6 Fermented *Gynochthodes officinalis* (F.C.How) Razafim. & B.Bremer alleviates diabetic erectile dysfunction by attenuating oxidative stress and regulating PI3K/Akt/eNOS pathway. **2023**, 307, 116249 0
- 5 Advanced hydrogels: New expectation for the repair of organic erectile dysfunction. **2023**, 19, 100588 0
- 4 Erectile Dysfunction after Radical Prostatectomy. **2020**, 1, 29-34 0
- 3 A first Tunisian pilot study investigating sexual dysfunctions in patients with hemophilia.. 12, 305 0
- 2 Venous Leak Embolization in Patients with Venogenic Erectile Dysfunction via Deep Dorsal Penile Vein Access: Safety and Early Efficacy. 0

1 Current trends in pharmacotherapy of erectile dysfunction. **2023**, 37, 5-9

o